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Abstract
Carbohydrates are a class of molecule occurring widely in the body. Their presence has
varied biological implications, generating clinical interest regarding their impact on disease
prognosis. This thesis will investigate the development of chemical entities surrounding two
carbohydrates, hyaluronan and inulin.
The Receptor for hyaluronan mediated motility (RHAMM) is one of several receptors for
hyaluronan (HA), a polysaccharide that, when fragmented, has pro-angiogenic and
inflammatory properties. RHAMM expression is tightly regulated during homeostasis but
increases in response to cellular stress, including during injury or disease states. HARHAMM interactions stimulate the Ras-ERK-Mek pathway to promote cell motility,
differentiation, and proliferation. Specific inhibition of HA-RHAMM interactions could have
significant therapeutic potential.
Chapters 2 and 3 explore two platforms for disrupting HA-RHAMM interactions. Chapter 2
discusses development of a 62-amino acid chemically synthesized truncated RHAMM
protein, 7 kDa RHAMM, for use in screening novel therapeutics. This mini-protein exhibited
similar secondary structure, bioactivity, and HA-binding capabilities as the full-length
protein, and binds known RHAMM-binding peptides with similar affinities as recombinant
RHAMM. This suggests that it is a suitable replacement for the difficult-to-obtain
recombinant version. Chapter 3 discusses the development of double stapled RHAMM
peptide mimetics as therapeutic anti-inflammatory agents. The peptides were evaluated for
secondary structure, HA-binding capability, and inflammation-related bioactivity. The lead
compound blocked 27.2% and 52% of induced inflammation in culture and in vivo,
respectively. The lead peptide was further optimized to improve metabolic stability while
maintaining secondary structure and HA-binding affinity, improving therapeutic efficacy.
Glomerular filtration rate (GFR) is a measure of kidney function and a prognostic indicator
of chronic kidney disease. Filtration of the polysaccharide inulin is the gold standard for
measuring GFR clinically, as it is neither reabsorbed nor secreted by the kidneys; however,
this method is laborious and invasive. Chapter 4 explores the development of a near-infrared
dye-labeled inulin, Cy7.5-inulin conjugate, as an optical probe to accurately and nonii

invasively measure GFR by transcutaneous pulse dye densitometer. The conjugate was
characterized by different analytical techniques, and is stable under in vivo conditions. The
probe was successfully used in a pig model to accurately measure GFR non-invasively.
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Introduction
Hyaluronan

Hyaluronan (HA) is a simple linear extracellular matrix polysaccharide that belongs to
the glycosaminoglycan (GAG) family of macromolecules and consists of dimeric repeats
of N-acetylglucosamine followed by D-glucuronic acid (Figure 1.1). In homeostatic
tissues, the majority of HA occurs in its high molecular weight (HMW) and native form
(e.g. >500 kDa), which is organized into scaffolds and matrices of the extracellular
matrix (ECM) [1, 2], making it a ubiquitous component of the ECM. The ECM
environment is tightly regulated during normal physiological conditions, providing
important structural and biochemical support to surrounding cells [3, 4]. Its functions are
understudied, but at a minimum, it promotes tissue hydration, provides lubrication,
protects against mechanical damage, reduces proliferation, modulates immune
recognition, promotes expression of anti-inflammatory cytokines, and blocks macrophage
functions, such as phagocytosis [3, 5-10]. In contrast to homeostatic tissues, HA polymer
size in remodeling and diseased tissues is strikingly polydisperse, ranging from <10 kDa
to >500 kDa [11]. HA fragments are generated by reactive oxygen/nitrogen species
(ROS/RNS) and hyaluronidases that are produced during tissue stress and repair [5-9, 1214]. Fragmentation of polymeric HA drastically alters the functions of HA. Short HA
fragments are reported to promote pro-inflammatory cytokine expression/release as well
as regulate innate immune cell proliferation [15-17]. Thus, the specific function of HA
depends on the precise polymer size and the type of cell responding to the fragments [1821]. HA fragments activate multiple receptors, triggering different downstream events
depending upon the injury or disease context [2, 15, 22-25]. HMW HA binds to CD44,
while smaller fragments of HA bind to receptor for hyaluronan mediated motility
(RHAMM) [2]. It has been suggested that HA fragments can also inhibit the binding of
higher molecular weight HA to CD44 [2, 26, 27]. Thus, fragmented HA could impact
tissues by either directly binding specific receptors or by acting as an antagonist such that
they prevent the binding of larger HA polymers to their cognate receptors. These
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complex interactions control a variety of signaling pathways that regulate cell
adhesion/motility, mitotic spindle integrity and transcriptomes.

Figure 1.1. Structure of hyaluronan, depicting the dimeric repeat of D-glucuronic
acid and N-acetyl glucosamine

Receptor for hyaluronan mediated motility
(RHAMM)
RHAMM (gene name HMMR) is a largely hydrophilic protein that was originally
isolated from embryonic chicken heart explant cultures exhibiting high HA production
and increased cell migration. It is one of a number of HA receptors that are expressed on
immune cells that bind to complex mixtures of HA polymer sizes and activate pathways
required for an inflammatory or tumorgenic response. RHAMM exists in two
populations: intracellularly, where it exists in both the nucleus and the cytoplasm, and
extracellularly, where it is a cell surface glycosylphosphatidylinositol (GPI) linked
protein. RHAMM expression is tightly regulated and limited during homeostasis;
however, RHAMM mRNA expression transiently increases in response to injury or
cellular stress, such as inflammation and cancer, resulting in increased receptor protein
expression and export to the cell surface. Cell surface RHAMM is a HA co-receptor with
CD44, and the interaction between the three molecules stimulates the activation of the
mitogen activated pathway (MAPK) or the Ras-Mek-ERK pathway and the transcription
of genes involved in cell motility, differentiation and proliferation in pro-inflammatory
microenvironments (Figure 1.2) [28]. Thus, the specific inhibition of HA-RHAMM
interactions could have significant therapeutic potential in cancer and other diseases.
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Figure 1.2. The interaction between cell surface RHAMM and HA activates the RasMek-ERK pathway, and the phosphorylation of ERK1,2, which results in active
transcription of mitogenic genes (A). Increased cytoplasmic RHAMM expression
also results in phosphorylation of ERK1,2, and therefore, the transcription of
mitogenic genes (B). Increased nuclear RHAMM expression results in aberrant
mitotic activity and genomic instability (C). All of these increases in RHAMM
expression result in the release of inflammatory cytokines and cellular migration
and proliferation. Adapted from [29].
RHAMM interacts with HA via two HA binding domains (HABDs) located near the
protein’s carboxyl terminus, each of which has a BX 7B binding motif, where B represents
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any basic residue and X represents any non-acidic residue [4]. These clusters of basic
residues allow for ionic interactions with the carboxylate ions of HA [4].
In addition to being a cell surface receptor for HA, RHAMM binds to extracellularregulated kinase (ERK) kinase, and regulates the expression of ERK [30]. ERK has two
closely related isoforms (ERK1 and -2) that are required for cellular differentiation and
proliferation [28, 30]. RHAMM is also a microtubule-associated protein (MAP) that
binds directly to microtubules and interacts with TPX2, a different MAP that is required
for microtubule formation [31]. RHAMM localizes to the centrosome, where it interacts
with tubulin and helps to maintain mitotic spindle integrity and polarity [32] (Figure
1.3). TPX2 initiates the formation of microtubules at the kinetochore, and activates
Aurora kinase A (AURKA), which accumulates at the centrosome from S phase to the
end of mitosis and facilitates the formation of microtubules [33-35]. This results in
centrosome maturation and spindle assembly [33]. High expression of AURKA results in
aberrant mitotic spindle formation, and is, therefore, correlated with genetic instability
and poor prognosis in human diseases [36].

Figure 1.3. RHAMM binds to microtubules and TPX2, and localizes at the
centrosome, where it also binds to tubulin (A). TPX2 initiates the formation of
microtubules at the kinetochore and activates AURKA (B). AURKA complexes with
TPX 2 (C) and accumulates at the centrosome (D). Adapted from [32].
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While RHAMM expression is tightly regulated or absent in most tissues, it is important
for a number of wound repair processes that require cell migration, invasion, and
remodelling of the ECM. Its restricted expression makes it a potential target for cancer
and wound repair therapy with low toxicity. RHAMM peptides are currently being tested
in phase II clinical trials for multiple myeloma and myelodysplastic syndrome and are
showing efficacy and low toxicity in patients [37, 38].

Peptide synthesis
Peptides can be synthesized chemically by two main techniques, solid phase peptide
synthesis (SPPS) and solution phase peptide synthesis. Solution phase peptide synthesis
can be more problematic than its solid phase counterpart, as dimerization and the
formation of other unwanted by-products requires the purification after the addition of
each amino acid.
In the early 1960s, Merrifield pioneered the idea of SPPS, using a polystyrene-based
solid support for peptide synthesis, which would deal with the difficulties associated with
solution phase synthesis [39]. The technique of solid phase peptide synthesis covalently
links the peptide chain to an insoluble resin, which acts as a solid support off of which the
peptide chain can grow or elongate. The solid support facilitates the addition of excess
soluble reagents in order to drive each reaction to completion, and the excess reagents
can be easily removed by multiple washing and filtration steps, eliminating the need for
tedious purification steps after the addition of each amino acid [39]. Following synthesis,
the crude peptide is released from the solid support and purified by traditional HPLC
methods, with higher yields often reported for SPPS than for solution phase methods
[39]. SPPS can be performed either manually or using an automatic peptide synthesizer,
which is convenient, and improves throughput.
Peptide synthesis by the SPPS strategy is carried out in a stepwise procedure that builds
the peptide chain from the C- to the N-terminus using Nα- protected amino acids. The
first amino acid is loaded onto the resin, which is functionalized with linkers for easy
loading, and the chain is elongated as subsequent amino acids are coupled together. Once
the peptide has been synthesized in its entirety or the desired peptide length has been
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achieved, it can be removed from the resin, yielding the free and linear peptide (Figure
1.4). Similarly, the synthesis can be monitored by LC-MS at any point during the
synthesis by removing a small aliquot of resin and cleaving the peptide off of it.

Figure 1.4. General scheme of solid-phase peptide synthesis
Successful SPPS depends on the choice of resin used. Resins are insoluble polymers that
are pre-loaded with varying linkers, which provide flexibility during synthesis, and allow
for control over the final product by determining the functionalization of a cleaved
peptide [40]. For example, Rink amide resins are functionalized with an amine group that
covalently binds to the first amino acid in the sequence to obtain an amide bond at the
carboxyl terminus of the peptide. In addition, resins can have different substitution levels,
which when decreased, facilitate the synthesis of long peptides by avoiding interchain
crowding, resulting in improved the synthetic yields [41].
One of the most common methods for synthesizing peptides by SPPS is through the 9fluorenylmethoxycarbonyl (Fmoc) strategy, which was first introduced by Carpino and
Han in 1970, in which amino acids are N-terminally protected [42]. This method employs
an orthogonal scheme that allows the removal of only the N-terminal Fmoc protecting
group without disrupting the remainder of the peptide. This is accomplished by mild
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basic conditions for the removal of the Fmoc group from each amino acid in order for the
next amino acid to be added, and by the strong acidic conditions that are required to
liberate the peptide from the resin, as well as remove all of the acid-labile side-chain
protecting groups.
Fmoc-based SPPS is carried out as depicted in Scheme 1.1. A protected amino acid is
added to the resin through standard coupling procedures to form an amide bond. The Nterminal Fmoc group of the amino acid is then deprotected with piperidine, resulting in a
free amine. The remainder of the peptide sequence is built following the same procedure
until the final peptide length is acquired. The free peptide is then obtained by treatment of
the resin with acid in order to simultaneously deprotect amino acid side chains and
remove the peptide from the solid support.
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Scheme 1.1. Fmoc-based solid-phase peptide synthesis

Rational design of peptides
Targeting a protein-polysaccharide or protein-carbohydrate interaction is often
challenging, as there is a large surface area of interaction and a lack of well-defined
binding pockets that prevent the use of small molecules for interfering with these binding
interfaces and inhibiting the interaction. Similarly, a challenge exists in trying to develop
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mimics that contain the specific multivalences that will foster interaction with its target
[43]. This is further complicated by the conformational changes that these HA receptor
proteins undergo upon binding to HA [44]. Higher molecular weight entities such as
peptides, proteins, and antibodies are more readily able to block protein-polysaccharide
interactions due to their ability to interact over a larger surface area.
The discovery of peptides that modulate protein-carbohydrate interactions has focused
largely on two approaches: unbiased or random peptide library screening and rational
design based upon known structure or binding sites. Unbiased peptide library screening
has used phage display, which is a biochemical approach to identify high affinity peptides
displayed on a bacteriophage, and one-bead one-compound (OBOC) libraries, which is a
chemical approach of screening peptides using polymer beads. These unbiased peptide
libraries were primarily used for identifying peptide mimetics that scavenge HA and HA
fragments. The discovery approaches used for finding HA binding peptides that mimic
HA receptors have primarily been based upon rational design, with many structural leads
being derived from RHAMM’s known binding sites for HA.
In many cases, the rational design of targeting peptides can start with a known crystal
structure of the peptide, which provides important information on the compound’s
secondary and tertiary structure [45]. Based on the initial crystal structure, alanine scans,
small focused libraries, and structure-activity relationship (SAR) studies are carried out in
order to identify the essential amino acids and sites for possible modification. This
process allows for the identification of those amino acids that are unstable and
susceptible to events such as isomerization, glycosylation, or oxidation [46]. In addition
to optimizing the peptide’s sequence, rational design involves improving the
physicochemical properties of natural or native peptides. This is often carried out by
introducing structural constraints, such as staples to cyclize the peptide the backbone, and
unnatural amino acids for use as pharmacologically active building blocks. Rational
design of a compound must account for target affinity and specificity, biological stability,
and its pharmacological and pharmacodynamics properties [45].
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Peptides as therapeutics
Targeting a specific receptor or other class of target can be achieved with a number of
different classes of molecules, including small molecules, peptides, or antibodies. There
are advantages and disadvantages to using the different classes of compounds. Small
molecules have relatively low molar mass, and therefore, can access many biological
targets in the body. In addition, small molecules are not easily recognized or degraded by
enzymes; however, they unfortunately suffer in lipophilicity, and because of their small
surface area, suffer from nonspecific interactions, which can lead to toxicity [47].
Peptides, on the other hand, can be synthesized by standard synthetic protocols, and
improvements in manufacturing technology have allowed for peptides of various length
ranges up to 40 amino acids to be synthesized, as well as quick and easy synthesis of
peptide analogues [48, 49].
Peptide-based drugs are generally shorter than 50 amino acids in length, with molecular
weights that lie between those of small molecules and large biologics [50]. Peptides as a
class of molecule are particularly attractive as drug candidates because they are
biocompatible with typically low toxicity, structurally diverse permitting high selectivity
and potency, and have a predictable metabolism [51]. These features have enabled
peptides to have high affinity for their targets at nanomolar and picomolar concentrations.
Unfortunately, peptides suffer from a relatively short circulating half-life because they
are susceptible to the same digestive enzymes designed to break down amide bonds of
ingested proteins, and can be cleaved by both endopeptidases and exopeptidases. As a
result, they have poor oral bioavailability and are quickly eliminated [45]. In addition,
they are prone to hydrolysis and oxidation, and have low membrane and tissue
permeability due to their polarity and relatively high molecular weight [45]. However,
there has been an increasing number of commercially available unnatural amino acids
and strategies that have helped improve the stability and other physical properties of
peptides. For example, the identification of possible cleavage sites within the peptide
sequence and the substitution of relevant amino acids is a preliminary approach to
limiting enzymatic degradation of the peptide. Novel synthetic strategies supplement this,
including modifications to amino acids or the peptide backbone, the incorporation of
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unnatural amino acids, the conjugation of additional moieties that extend half-life or
improve solubility, and cyclization of the peptide backbone with synthetic structural
constraints, which may stabilize the peptide’s secondary structure [48, 52].

Current peptide mimetics that inhibit RHAMM-HA
interactions
1.6.1 Rationally designed peptide mimetics
To date, several peptide mimetics have been rationally designed to interfere and block the
HA-RHAMM interaction. RHAMM-sequence based peptide mimetics that bind to HA
fragments and have been shown to have therapeutic effects in a number of processes,
including inflammation, wound repair, and fibrosis/adipogenesis. One of the first
rationally designed HA-binding peptides was based on the RHAMM BX7B HA binding
motif, but does not otherwise have any amino acid sequence homology with RHAMM.
This peptide strongly reduced BAL macrophages in bleomycin-induced lung injury and
blunted destruction of lung architecture [53], reduced surfactant protein A-induced
macrophage chemotaxis [54] and ozone induced lung hyper-responsiveness [55]. Another
peptide, pep-35, has 70% homology with the RHAMM sequence and essentially joins
four RHAMM HA binding sequences together. This peptide reduced Staphyloccus
aureus burden in infected surgical wounds and increased the production of CXCL1,2 by
inflammatory cells, which subsequently increased neutrophil influx into the wound [56].
Other peptides have been designed to mimic the three BX 7B motifs of CD44 and were
shown to block tumor cell growth [57]. Finally, RHAMM sequence mimics (NPI-0102,
NPI-0104), which disrupt HA binding to RHAMM, were reported to promote
adipogenesis and reduce tissue fibrosis [58] by increasing the production of adiponectin,
an anti-fibrogenic adipokine [59, 60].
In another rationally designed approach, Esguerra et al. developed HA peptide mimics
from the C-terminal region of - and -tubulin that bind to RHAMM [61]. Novel 12mer
peptide ligands were identified that bind with high affinity (nM) to RHAMM and block
HA binding to tumor cells [61]. The strongest binding compounds were taken from the
negatively charged carboxy terminal tail (CTT) and the helix H12 regions of tubulin, and
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those that contained a repeating amino acid motif of EEXEE, suggesting that both
electrostatic forces and conformational effects may be important for the development of
RHAMM-binding ligands.
Other RHAMM peptide-based therapies could reasonably be developed from varying the
peptide backbone and/or altering the peptide structure, which may confer improved
specificity and affinity towards its target. Such strategies include the development of
stapled or cyclized peptides, resulting in more drug-like compounds.

1.6.2 Peptide library screening for HA- and HA receptor-binding
In addition to rational design, many peptides with therapeutic potential were discovered
through peptide library screenings. The P15-1 peptide (STMMSRSHKTRSHHV) is a
15mer peptide, which was the first peptide mimetic that was reported to bind specifically
to HA fragments of <10 kDa. It was identified by screening a recombinant phage display
library with a complexity of approximately 1013 transformants for peptides that both bind
to HA fragments (MW range 5-200 kDa) linked to Sepharose beads and that block cell
motility [62]. Two peptide sequences were recovered in the screen and of these, P15-1
exhibited the highest affinity for HA fragments (K D = 10-7 M), and most strongly blocked
cell motility. It has low homology with known HA receptors but contains a BX 7B motif
similar to that required for binding of HA to RHAMM [4]. In a model of excisional skin
injury, P15-1 blunted inflammation and fibrogenesis [62]. Consistent with the proposed
possibility that P15-1 blocks RHAMM signaling though HA fragments, the consequences
of this peptide mimetic on skin wound repair is similar to that of the genetic deletion of
RHAMM [28], which results in blunted responses to HA fragments [63]. For example,
both conditions block inflammation and fibrogenesis in excisional wounds but neither
affect the course of incisional wound repair, which does not involve the massive waves of
cellular trafficking and migration that are required for the healing of excisional wounds
[28, 64, 65]. P15-1 synthesized entirely with D-amino acids (referred to as HABP42) also
reduced bacterial burden in surgical skin wounds by modulating neutrophil responses [56,
66].
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Pep-1, a 12mer peptide (GAHWQFNALTVR) was identified as an HA binding sequence
by screening an M13 phage display library expressing random 12mer peptides fused to
gene 3 (pIII) minor coat proteins with a complexity of approximately 10 9 transformants
[67]. This peptide (Pep-1) was isolated by panning the library for sequences that bind to
HA-coated plates. Pep-1 binds to HA with moderate affinity (KD = 1.4 µM), inhibits HA
binding to innate immune cells, and was shown to inhibit leukocyte attachment to HA
substrates [67, 68]. The systemic, subcutaneous or topical administration of this peptide
inhibited dinitrofluorobenzene/oxazolone induced-contact hypersensitivity by blocking
both the in-trafficking of inflammatory cells and the migration of dendritic cells out of
the epidermis [67]. Skin dendritic cells utilize HA as a motogenic stimulus for migrating
from the epidermis to lymph nodes, where they function as antigen-presenting cells, a
process that is required for generating protective pro-inflammatory and tolerogenic
immune responses during tissue injury [69, 70]. Aberrant activation of these cells
contributes to inflammatory disease processes [70]. These results provided early support
for the development of HA inhibitors for inflammatory disorders. Pep-1 was later shown
to inhibit the production of fragmented HA-promoted chemokine MIP-2 by bone marrow
macrophages [71], reduce bronchial inflammation [72], reduce pro-inflammatory
cytokine production (TNF-α, IL-6, MMP13 and iNOS), and preserve cartilage
architecture in a mouse model of collagen-induced arthritis [69, 73]. In addition, Pep-1
dramatically inhibited interleukin-2 (IL-2)-induced vascular leak syndrome (VLS) [74],
which may be linked to its anti-inflammatory effects. P15-1 and Pep-1 have been useful
in dissecting the signaling pathways that are regulated by HA fragments, and their
efficacy in blocking inflammation in animal models propelled the development of peptide
mimetics that block fragmented HA-induced activity that leads to disease.
Recombinant CD44 protein has also been used to screen peptide libraries [75]. In this
study, a Ph.D.TM -12 phage display peptide library with a peptide complexity of 2.7x10 -9
transformants was screened using recombinant CD44 as bait. The screen isolated several
peptides, one of which exhibited a KD = 7.5 pM for recombinant CD44. However, none
of the isolated peptides were tested for their ability to bind to the CD44 HA binding
region or evaluated for functional effects. Nevertheless, these studies show that isolating
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peptides that bind to HA receptors is a viable approach for potentially developing novel
inhibitors of HA receptor signaling.
Peptide-displaying phage and peptide library technology have also been used to identify
peptides that mimic carbohydrates [76]. HA peptide mimics that bind with high affinity
to recombinant RHAMM containing hyaluronan binding sequences, were originally
identified by Ziebell, M. et al [77, 78]. Two libraries of 8mer peptides were designed to
target recombinant RHAMM fragments, with one library consisting of peptides made of
entirely random sequences. The second library was biased, with alternating acidic
residues incorporated in every other position of the sequence, with the intention of
mimicking the placement of the glucuronic acid moieties of HA [77]. Peptides from the
unbiased (random) library bound to recombinant RHAMM in an HA fragment-dependent
manner with µM to nM affinity, and exhibited some similarities with respect to regions of
hydrophobic residues (e.g. PVY), but contained very few negatively charged amino
acids. These peptides were then computationally modeled to evaluate their binding to an
NMR-based model of RHAMM, from which residues within RHAMM were identified
and theorized to stabilize RHAMM-HA interactions [78]. However, these peptides have
not yet been reported to affect cellular functions.

Protein-Carbohydrate interactions
There are a number of proteins that bind glycosaminoglycan carbohydrates, and many of
the binding partners have been studied extensively. Generally, the main interaction
between GAGs and the proteins that bind them are strong ionic interactions between the
highly acidic sulphate or carboxylate groups of the carbohydrates and the basic side
chains of arginine, lysine, and to a lesser extent, histidine residues of the protein [79].
GAGs interact with those residues that are exposed and easily accessible on the surface of
proteins. Aliphatic residues, including Ala, Gly, Leu, and Ile, and other hydrophobic
residues, such as Pro, Phe, Met, and Trp, are usually buried on the inside of proteins, and
therefore, do not appear to participate in sugar bonding, while more polar and charged
residues, such as Asn, Asp, Glu, Gln, His, Arg, and Lys, have been shown by both
structure and sequence-based statistical analysis to bind to non-sulfated carbohydrates
[80-82], such as heparin and hyaluronan. It is common for clusters of basic amino acids
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to exist on proteins, which facilitates the protein’s interaction with the negatively charged
groups of the sugar. Heparin-binding proteins have been identified as having binding
sites with sequences of XBBXBX or XBBBXXBX, where B is any basic residue, and X
is any non-acidic residue [83]. Similar binding sequences have been observed in HAbinding proteins, such as RHAMM and CD44, both of which exhibit a BX 7B binding
motif [4]. Depending on the secondary structure of the protein, it is possible that very few
residues in these binding sequences actually contribute to or participate in binding. For
example, when the binding domains are arranged in an alpha-helix, the basic residues are
often found along one exposed face of the protein, resulting in an amphipathic helical
arrangement [84]. Therefore, in order for an interaction to take place between linear
carbohydrates, such as HA, and largely helical proteins, such as RHAMM, the positively
charged residues arrange themselves so that they are on the same face of the protein
segment (Figure 1.5).

Figure 1.5. In an alpha-helix, the basic residues are often found along one exposed
face of the protein, resulting in an amphipathic helical arrangement.
Biochemical assays are used to evaluate protein-carbohydrate interactions and can be
carried out by chemically modifying the entities being evaluated, such as in the case of
enzyme-linked immunosortbent assay (ELISA), or without modifying either entity, such
as in the case of surface plasmon resonance (SPR). ELISA has the potential to be the
more high-throughput method of screening, allowing the binding of several compounds
to be evaluated simultaneously against either a single or multiple targets [85]. This assay
requires that compounds be labeled or chemically modified, such as with a dye or biotin

15

molecule, for signal readout. SPR, on the other hand, is a label-free method for evaluating
biomolecular interactions, measuring single concentrations of compound at a single time,
decreasing the throughput of measurement compared to ELISA. Despite this, label-free
methods of evaluating the interaction between two compounds is especially important for
small proteins or peptides, as secondary structure often influences binding, and
chemically modifying these molecules can potentially alter their secondary structure. In
addition, unlike ELISA, SPR delivers a kinetic analysis of the interaction in addition to
the binding affinity in real-time, providing information on the association (ka) and
dissociation (kd) phases of the interaction.

Figure 1.6. Analyte binding to the immobilized ligand at the sensor chip surface
results in a change in resonance angle of reflected light. The Langmuir model with
mass transport limitations describes the relationship between on (ka) and off (kd)
rate constants, taking into account the rate at which analyte is brought from the
bulk solution to the sensor chip surface. Adapted from Nicoya Lifescience.
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The principle of SPR utilizes the immobilization of a compound of interest, known as the
ligand, to a metal-coated sensor chip surface, and the measurement of changes in
refractive index at the surface as another molecule, the analyte, binds. A light source
shines light or a laser on the metal-coated film, reflecting with a resonance angle

that

shifts when a binding event occurs at the sensor chip surface, resulting from a change in
refractive index (Figure 1.6). This shift depends on the mass and density of analyte at the
chip surface. In this thesis, a variation of SPR, localized SPR (LSPR), was studied. LSPR
differs from traditional SPR by using gold nanoparticles at the sensor chip surface instead
of the continuous metal film used in traditional SPR. In addition, LSPR produces a strong
resonance absorbance peak, with its position being highly sensitive to the refractive index
localized around the nanoparticles. As a result, it measures changes in the wavelength of
the absorbance position resulting from binding events rather than changes in angles
(Figure 1.7), like is measured in traditional SPR.

Figure 1.7. Analyte binding causes a shift in wavelength of absorbance position in
localized SPR (LSPR). Adapted from Nicoya Lifesciences.
Following immobilization of the ligand to the sensor chip surface, the remaining binding
sites are blocked in order to prevent non-specific interactions between the analyte and the
chip surface. As the analyte flows across the immobilized ligand surface, and interacts or
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associates with it, it accumulates on the chip surface, resulting in a change in molecular
weight at the chip surface, which is denoted by a change in signal. The rate of association
between the two compounds depends directly on the on-rate of the interaction (ka) and
the mass transport of the analyte from the bulk flow to the sensor chip surface (k m). Once
the flow of analyte switches to buffer, the analyte dissociates from the chip surface,
resulting in a decrease in signal (kd). A strong ligand-analyte interaction requires the use
of a regeneration buffer to completely remove analyte from the chip surface, while
leaving the immobilized ligand in-place.
An important consideration in SPR is that tethering the ligand to the sensor chip surface
will not disrupt its activity, prevent rotational freedom, or block any sites of binding.
Therefore, the correct method of immobilizing one of the binding partners to the sensor
chip surface is important. Biomolecule immobilization can be either direct, by covalent
interaction with the sensor chip surface, or indirect, by binding to an immobilized
capturing molecule [86]. Examples of direct immobilization include biotin-streptavidin
interactions, gold-thiol interactions, and amine-carboxylic acid interactions. In many of
these instances, orientation of these proteins is difficult to control, resulting in mixed
orientations of protein on the surface, and the interaction can be so strong that
regeneration of the sensor chip surface is not possible, such as with biotin-streptavidin
interactions [87]. An alternative approach is to indirectly immobilize a biomolecule by
labeling it with an oligo histidine tag (His tag) at either its C- or N-terminus, which
interacts with nitrilotriacetic acid (NTA) that is pre-immobilized on the sensor chip. This
method of attachment involves the capture of the His-tag protein by Ni2+ NTA chelation
without altering secondary structure or blocking important analyte-binding residues, and
allows for regeneration of the sensor chip. The exact immobilization chemistry depends
on the specific interaction that is being evaluated.

Stapled peptides
1.8.1 Alpha-helices
Protein secondary structure is broken down into conformations that are in an alpha-helix,
a beta-sheet, or a random coil. The Protein Data Bank (PDB) consist of approximately
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62% alpha-helical proteins, suggesting that the alpha-helical conformation plays an
important role in mediating a number of biological processes, including interactions with
other proteins and macromolecules [52, 88].
There is a high energy requirement associated with organizing three consecutive amino
acids into a helical conformation, which is referred to as the helix-coil transition theory
[89]. Many short peptides lack a helical structure, as the energy required to organize them
into well-defined helices is too great. However, pre-folding short peptides synthetically
has the potential to overcome this energy barrier and can therefore facilitate the adoption
of a stable secondary structure, such as an alpha-helix.

1.8.2 Stapled peptides
One complete turn of an alpha-helix is made up of 3.6 amino acids, resulting in the
residues at positions i, i+4, and i+7 occurring on the same face of the helix [52].
Synthetically, the alpha-helical conformation of a peptide is carried out by introducing a
covalent bond, or “staple”, at these amino acids positions, stabilizing the structure and
inducing an alpha-helical conformation [90]. The positions of these staples can be
important, however, and care must be taken in order to not replace or obstruct those
residues that are important for binding to the target. Four methods for synthesizing
stapled peptides have been extensively studied thus far, and include their formation by a
lactam bridge, a hydrocarbon chain, a metal-ion clip, and a hydrogen bond surrogate [50,
52]. Staples formed by a hydrocarbon chain and lactam bridge are the preferred methods
of peptide cyclization for the improvement in bioactivity and target recognition that they
confer [91].
Staple formation in peptides depends on the linear peptide sequence and can only take
place if the unfolded peptide sequence has the natural propensity to adopt an alphahelical conformation. If the peptide sequence is unable to naturally adopt an alpha-helical
conformation, it is possible that the side chains forming the staple will not arrange
themselves appropriately, and therefore, will not bridge. Staple length depends on the
size of the ring that is created following bridging, with shorter staples between side
chains decreasing the peptide’s flexibility, and resulting in a more stable helix [90].

19

Amino acid side chains should produce a staple length or size that is large enough to not
cause significant ring strain, and therefore, decrease the demand for activation energy for
successful cyclization to be completed [92]. Side chains involved in creating the linker do
not contribute to target recognition, and therefore, block at least one face of the helix
once the staple is created.
A lactam bridge is created by means of an amide bond that forms between the side chains
of two amino acids. Natural amino acids, glutamic acid or aspartic acid and lysine, are
commonly applied to make the lactam bridge, but unnatural amino acids, such as
ornithine and aminoadipic acid, can also be used. During synthesis, orthogonallyprotected glutamic acid and lysine residues replace the amino acids of the natural peptide
sequence in the appropriate positions (i.e. positions i, i+4, i+7, i+11). The peptide chain is
built on resin following standard Fmoc-based SPPS procedures, allowing for the selective
deprotection of the two amino acid side chains forming the lactam bridge, and their
subsequent coupling to staple the peptide backbone and yield the cyclized product.
Specifically, allylester and alloxycarbonyl protecting groups on glutamic acid and lysine
side chains, respectively, are deprotected with palladium (0) catalyst under basic
conditions, and the deprotected side chains are coupled together with a coupling agent,
such as 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid
hexafluorophosphate (HATU). The remainder of the peptide sequence can be modified as
necessary, and eventually removed from the resin, with the staple intact (Scheme 1.2).

Scheme 1.2. General synthetic protocol for the formation of a lactam bridge between
glutamic acid and lysine residues
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1.8.3 Circular Dichroism spectroscopy
The secondary structure of proteins and peptides can be analyzed and quantified by
analytical techniques, such as circular dichroism (CD) spectroscopy, which measures the
extent to which asymmetric molecules can absorb right- and left-handed circularly
polarized light [93]. The amide bonds in the primary sequence of proteins and peptides
contain chromophores that produce different excitation interactions, resulting in
identifiable characteristics on the spectra [94]. Each type of secondary structure produces
a unique CD spectrum, which are blended together when different secondary structure
elements exist within a single compound. The CD spectrum of a perfect alpha-helix (3.6
amino acids per turn) is characterized by two minima at 222 nm and 208 nm, and a
maximum at 193 nm, but these signals may shift in wavelength or in intensity if the
compound contains elements of -sheet or random coil within its structure [94]. Many
large proteins are made up of multiple secondary structure elements, and many small
stapled peptides lack a perfectly stable secondary structure beyond the stapled sequence.
In both of these cases, the CD spectrum is unlikely to reflect a perfect single secondary
structure.

Glomerular filtration rate
Glomerular filtration rate (GFR) measures renal clearance, and can therefore, be a
valuable tool in assessing kidney function and identifying the presence of chronic kidney
disease (CKD) or other diseases that may target the kidneys. GFR may also be used for
monitoring kidney function following kidney transplant, and therefore, identifying threats
associated with organ rejection and nephrotoxicity.
The gold standard for measuring GFR is by directly measuring plasma clearance of a
marker molecule or compound that filters freely through the glomeruli and is neither
metabolized nor reabsorbed through the renal tubules. Inulin, a polysaccharide made of
up of a single glucose unit and many fructose units, has been accepted as the marker of
choice for quantifying GFR.
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Figure 1.8. Structure of inulin
In the classic method for measuring clearance by Homer Smith, patients receive a
continuous intravenous infusion of inulin following a period of fasting, multiple
collections of blood and urine samples at precise times over 3 hours, and bladder
catheterization in order to ensure complete urine collection [95]. Because this method of
determining GFR is time-consuming, impractical, and invasive for patients, the clinical
practice of using inulin has decreased, and the common clinical practice has been
replaced with measuring the clearance of endogenous markers, such as serum creatinine
levels, which provide an estimated GFR (eGFR) value quickly for clinical decision
making using the Modification of Diet in Renal Disease (MDRD) Study equation [96] or
the Cockcroft-Gault formula [97].
Cockcroft-Gault formula:
𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =

(140 − 𝑎𝑔𝑒 𝑖𝑛 𝑦𝑒𝑎𝑟𝑠) × (𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑘𝑔)
𝑚𝑔
(72 × 𝑠𝑒𝑟𝑢𝑚 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 𝑖𝑛
)
𝑑𝐿

The value is multiplied by 0.85 if the individual is female.
MDRD formula:
𝐺𝐹𝑅 = 186.3 × (𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 𝑙𝑒𝑣𝑒𝑙 𝑖𝑛
× 1.210(𝑖𝑓 𝑏𝑙𝑎𝑐𝑘)

𝑚𝑔 −1.154
)
× 𝑎𝑔𝑒 0.203 × 0.742 (𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒)
𝑑𝐿
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Plasma levels of endogenous filtration markers, such as creatinine, are determined by
their generation from cells and diet, renal excretion, including filtration through the
glomeruli, and tubular secretion and reabsorption, and elimination by the gut and liver
(Figure 1.9) [98]. Unfortunately, equations that estimate GFR consider only 4 variables:
age, gender, race, and body weight. Factors that influence muscle mass or diet, changes
in diet or muscle mass due to illness or amputation that are not considered, and
differences in race other than those considered in the equation, result in inaccuracies that
underestimate the normal physiologic GFR value.

Figure 1.9. The plasma level of endogenous filtration markers depends on their
generation (G) from cells and diet, elimination (E) by the liver and gut, and urinary
excretion (U) by the kidneys. Urinary excretion includes filtration, tubular secretion
and reabsorption. Under homeostatic conditions, U = G+E. Adapted from [98].
In order to improve the efficiency and accuracy of GFR measurements, several
alternative exogenous tracer agents [98] have been developed, all of which allow for realtime measurement of kidney function by monitoring the decay of a bolus infusion of the
reporter molecule from the plasma or the extracellular space over a period of time [99].
These alternative techniques include the use of radioisotope-labeled probes, such as 125Iiothalamate [100], 51Cr-ethylenediaminetetraacetic acid (EDTA) [101], and 99mTcdiethylenetriaminepentaacetic acid (DTPA) [102, 103], as well as non-radioactive probes,
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including iohexol [104], unlabeled iothalamate [105, 106], FITC-labeled sinistrin [107,
108], and FITC-labeled inulin [109, 110]. Methods for detecting these reporter molecules
have included corometric assays, scintillation counting, X-ray fluorescence, HPLC,
visible fluorescence, and two-photon intravital microscopy [99]. While many of these
techniques are useful for developing and evaluating probes, they can be costly and are not
easily translated to a clinical environment. In addition, these alternative probes have all
been found to underestimate GFR, suggesting that they might be suffering from tubular
reabsorption or plasma protein binding [98].

Rationale of thesis
This thesis will focus on two separate frameworks. The first framework encompasses
chapters 2 and 3, studying the protein-carbohydrate interaction between RHAMM and
HA and developing tools that inhibit it, while the second framework is discussed
exclusively in chapter 4, involving a different carbohydrate, inulin, and the development
of an optical agent based on it. Chapter 2 describes the chemical synthesis and
optimization of a truncated RHAMM receptor, 7 kDa RHAMM, for use as the target
receptor in screening and discovering novel peptide ligands. Chapter 3 describes the
development of double stapled RHAMM peptide mimetics that bind HA with high
affinity, and that are active in blocking inflammation both in vitro and in vivo. Chapter 4
describes the development of a dye-labeled inulin conjugate for measuring glomerular
filtration rate by transcutaneous pulse dye densitometry and has been evaluated in vivo in
farm-raised pigs.
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Chapter 2

2

A Truncated RHAMM Protein for Discovering Novel
Peptide Therapeutics
Introduction

The receptor for hyaluronan mediated motility (RHAMM, gene name HMMR) is one of
several proteins that bind to the polysaccharide hyaluronan (HA). HA is a high
molecular weight (HMW) anionic polysaccharide that is a major component of the
extracellular matrix in most tissues and is important to both tissue homeostasis and
response to injury processes. Thus, it regulates immune cell infiltration, and such cell
behavior as migration, proliferation, and adhesion [1-9]. These functional effects of HA
depend upon its molecular weight. For example, native HMW HA (>500 kDa) reduces
inflammation and angiogenesis while fragmented HA (<200 kDa) has pro-angiogenic, inflammatory and -fibrosis properties. Notably, fragmented HA accumulation is linked
to the progression of inflammation and fibrosis-based pathologies such as arthritis,
diabetes, and idiopathic pulmonary fibrosis [3, 4, 10, 11].
Full-length human RHAMM is an 85 kDa coiled-coil protein in humans (95 kDa in
mice) that occurs both in intracellular and extracellular compartments. It has highly
restricted and tightly regulated expression in most normal tissues [12], but is one of a
number of oncogenic proteins that are exported to the cell surface in response to tissue
stress by unconventional transport mechanisms. Cell surface RHAMM regulates both
cell motility and mesenchymal differentiation, while intracellular RHAMM is a
microtubule-associated protein (MAP) that binds to ERK1,2 [13] and also mediates
interactions of TPX2 with Aurora A kinase, which affects microtubule assembly [14].
Intracellular RHAMM localizes to interphase microtubules, the mitotic spindle and
centrosomes, and contributes to mitotic spindle integrity and orientation during mitosis
[13-18]. These RHAMM functions are required for mobilizing progenitor/stem cells and
innate immune cells during development [19] and normal tissue repair [20-23]. Deregulated RHAMM expression has been linked to both centrosomal abnormalities and
aberrant cell motility, which likely contribute to the genetic instability and invasion that
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fuels progression of many cancers. Elevated RHAMM expression is common in cancer,
and is prognostic of poor outcome, such as in oral squamous cell, breast and prostate
carcinomas [24-26]. The ability of fragmented HA to bind to RHAMM is key to its
signaling functions. RHAMM binds to HA fragments and interacts with CD44 and
growth factor receptors such as platelet-derived growth factor receptor (PDGFR),
epidermal growth factor receptor (EGFR) and members of the hepatocyte growth factor
receptor (HGFR) family [13, 27-32]. These interactions activate signaling pathways such
as the RAS/MEK1,2/ERK1/,2 cascade and promote AP1/TRE and NF B transcriptional
activity [3, 13, 27, 33] resulting in the expression of genes that promote cell growth and
differentiation, tissue remodeling [34-36], tissue morphogenesis [34, 37], matrix
organization, inflammation and angiogenesis, and cell trafficking [27, 38-41]. Thus, the
specific inhibition of HA-RHAMM interaction could have significant therapeutic
potential for preventing activation of HA-mediated signaling cascades.
RHAMM was originally isolated from the supernatants of chick embryonic heart
fibroblasts in culture as a 60 kDa isoform [42], and was subsequently cloned from
mesenchymal cells [43, 44]. Production and isolation of full-length RHAMM using
recombinant protein technology has proven difficult with low isolation yields. We
propose the chemical synthesis of a truncated version of the protein (706-767), 7 kDa
RHAMM, which contains the HA-binding region [45, 46], for use as the target receptor
in the screening of new RHAMM-binding peptides for the development of peptide-based
therapeutic agents for treating RHAMM-related disease.

Results and Discussion
2.2.1

Synthesis and purification of 7 kDa RHAMM

The therapeutic potential of RHAMM-binding peptides that inhibit cellular RHAMM-HA
interaction deserves investigation. RHAMM expression is tightly regulated and restricted
in healthy homeostatic tissues, but is overexpressed during cellular stress, including
tissue repair, chronic inflammation, and oncogenic processes. This makes RHAMM
protein an ideal candidate for therapeutic intervention. Synthesis of full-length RHAMM
by recombinant protein production methods has been described previously using
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glutathione-S-transferase (GST) recombinant fusion protein [47, 48], but elution of GSTRHAMM from a glutathione column and the subsequent removal of the GST tag with
thrombin results in a final yield of 0.06-0.13% (2-4 mg final yield following 3 g starting
material in the supernatant) for recombinant RHAMM protein that is the C-terminal 10
kDa fragment, with much lower yields for larger fragment sizes. The largest loss occurs
during the column elution step, and the treatment of the column with SDS to facilitate
protein elution compromises bioactivity. Thus, the biosynthesis of recombinant RHAMM
protein is difficult, resulting in very low yields. This has therefore directly hindered the
discovery and development of therapeutic agents that target RHAMM. Here, we
proposed and investigated the chemical synthesis of a truncated receptor that contains
both HA binding sites, affording it the HA binding properties that have been well
characterized of the native protein, and that can be readily synthesized by Fmoc-based
peptide chemistry in high purity. 7 kDa RHAMM (mRHAMM 706-767) is a 62-amino
acid mini-protein that bears the same amino acid sequence as that portion of the fulllength protein, including the two HA binding domains.
The RHAMM protein is predicted to be predominantly helical and binds to HA by
carboxyl-terminal positively charged amino acid clusters [49, 50] in contrast to CD44,
which binds to HA in a conformationally-dependent manner to a much larger link module
sequence [51]. We reasoned that synthesis of the carboxyl terminal RHAMM sequence
should retain its HA binding potential and provide much better yields than achieved
recombinantly. We therefore synthesized the aa706-767 fragment of mRHAMM, which
contains the HA binding sequence (Figure 2.1).
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Figure 2.1. 7 kDa RHAMM protein. (A) mRHAMM (706-767) sequence (B)
Depiction of 7 kDa RHAMM, showing the protein’s two hyaluronan binding
domains contained within two helices, as proposed by [50, 51].
7 kDa RHAMM was synthesized by automated Fmoc solid phase peptide synthesis, using
Rink amide MBHA resin (0.39 mmol/g loading) and Fmoc-protected L-amino acids.
Synthesis of 7 kDa RHAMM was carried out under microwave irradiation conditions,
with coupling reactions taking place at 75 C, with the exception of His residues, which
were done at room temperature in order to prevent racemization [52]. Synthesis was
performed on a 0.05 mmol scale, as initial attempts indicated that a 0.1 mmol scale did
not allow for adequate mixing of the resin during periods of vortexing. Purification by
automated HPLC resulted in a final product with a purity >95%. All expected charged
states until the [M+13H]13+ signals were observed, and the observed isotope pattern for
each charged state was as expected (Table S2.1).
A negative control mini-protein was synthesized under the same conditions as 7 kDa
RHAMM. All basic residues were replaced with alanine residues in both HA binding
domains, and we have therefore termed this control Ala-7 kDa RHAMM. Purification by
HPLC-MS resulted in a final product with a purity of >95%, and charged states were
observed until the [M+8H]8+ signals were observed. Characterization of 7 kDa RHAMM
RHAMM’s protein sequence is predicted to be largely hydrophilic and alpha helical, with
the HA binding domains contained in two tightly coiled coils that are separated by a
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central loop [50, 53]. The alpha helical structure of the HA binding domains results in the
alignment of the positively charged residues on the same face of the helix, where they
presumably interact with the negatively charged carboxylate ions of HA [50].

2.2.2

Characterization of 7 kDa RHAMM

The RHAMM protein sequence is predicted to be largely hydrophilic alpha helical, with
the HA binding domains contained in two tightly coiled coils that are separated by a
central loop [50, 53]. The alpha helical structure of the HA binding domains facilitates
ligand binding by ensuring the alignment of the positively charged residues on the same
face of the helix, where they presumably interact with the negatively charged carboxylate
ions of HA [49, 50]. The portion of the full protein that makes up the mini-protein
specifically has been reported to contain helices [50], and therefore, 7 kDa RHAMM is
expected to have a similar secondary structure as that portion of full-length RHAMM.
Structural analysis of 7 kDa RHAMM by CD spectroscopy confirmed that the miniprotein has an alpha-helical character (Figure 2.2). The ratio of the molar ellipticities at
the two minima defining helicity in a CD spectrum, [θ]222/[θ]208, is indicative of the
relative helicity of a compound; a compound is more helical when the ratio of these two
values approaches 1.0. 7 kDa was found to have a [θ]222/[θ]208 value of 0.86 in a water
solution. For this reason, despite truncation, the secondary structure of 7 kDa RHAMM
suggests that this part of the protein might have important secondary structure properties
needed for interaction with the protein’s native ligand, HA.
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Figure 2.2. 7 kDa RHAMM is helical by CD spectroscopy. CD spectrum of 7 kDa
RHAMM in water (0.5 mg/mL) showing alpha-helical character, similar to that of
the full-length protein’s predicted secondary structure [49, 50].

2.2.3

HA-binding

SPR was used to evaluate the mini-protein-carbohydrate interaction. 5-10 kDa HA was
immobilized on the SPR sensor chip surface by a gold-thiol bond. A concentration
dependent dose response was observed for the interaction between 7 kDa RHAMM and
HA, and in each case, a rapid rate of association, and a stable SPR signal were observed,
suggesting a strong interaction between the two compounds (Figure 2.3A). Indeed, 7
kDa RHAMM was determined to bind to HA with an average dissociation constant, K D
value, of 9.0 nM

0.2 nM. The dissociation constant between RHAMM protein and HA

was originally determined to be approximately 10 -8 M [44], but no reports have
confirmed the accuracy of this affinity range until now. Reports on the increase in
RHAMM expression in response to HA fragments ranging from 6 kDa HA to 100 kDa
HA [11], and the realization that HA fragments that range from 3 to 25 disaccharide units
(1.2-10 kDa) have inflammatory and pro-angiogenic properties in vitro [54] make the
observed binding between 7 kDa RHAMM and 5-10 kDa HA comparable to the cellular
receptor. We developed a negative control mini-protein, in which all of the basic residues
in both HA binding domains were replaced with alanine, thereby eliminating the
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characteristic BX7B binding motif of the HA binding domains, and theoretically
preventing the majority of HA binding through ionic interactions. This was indeed found
to be the result, yielding a dissociation constant of 3.2 M

0.6 M, which is almost a

400X weakening of the affinity compared with when the natural sequence is used in the
same size protein. In addition, the SPR signal resulting from the interaction between HA
and Ala-7 kDa RHAMM had a significantly lower signal to noise ratio than its 7 kDa
RHAMM counterpart, as well as a slower association and quicker dissociation,
suggesting a weak and less specific interaction. The residual binding that is observed,
however, is possibly the result of interactions that are not the predominant ionic
interactions of the two molecules, and may include other interactive forces that are
common among glycosaminoglycans and the receptors that bind them, such as van der
Waals forces, hydrogen bonds and hydrophobic interactions with the carbohydrate
backbone [7]. This stark difference in binding affinity between 7 kDa RHAMM and its
alanine counterpart highlights the importance of the basic charges to the RHAMM-HA
interaction, and that SPR can be used a successful tool in measuring interactions with the
mini-protein.

Figure 2.3. 7 kDa RHAMM binds HA by SPR. SPR signals showing the interactions
between immobilized 5-10 kDa HA and 7 kDa RHAMM (A) and a negative control
mini-protein, which had no basic residues in the HA binding domains (B). Each
signal corresponds to the responses of different HA concentrations, and solid lines
indicate a linear 1:1 interaction curve fitting model for the ligand-analyte
interaction. The dissociation constant was determined to be 9.0 nM for 7 kDa
RHAMM and 3.2 M for the negative control mini-protein.
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To confirm the interaction between HA and 7 kDa RHAMM, an enzyme linked
immunosorbent assay was carried out using biotinylated 7 kDa RHAMM on HA-coated
plates with an average polymer size of 1500-1800 kDa (Echelon). Binding between the
mini-protein and HA was found to vary with concentration, resulting in an effective
concentration (EC50) value of 0.30

0.05 M (Figure 2.4). This value differs from that

obtained by SPR, and can be explained by two major reasons: the difference in size of
HA used in the two techniques and the fact that in SPR, substrates are not fixed to the
surface of the biosensor, while in ELISA, HA is fixed to the plate, potentially resulting in
a different orientation of the carbohydrate, and specifically its carboxylate ions, than in
SPR. Nevertheless, the strong and highly specific interaction between 7 kDa RHAMM
and HA suggests that truncating the receptor to the 62-amino acids length of mini-protein
does not negatively impact HA binding, and therefore, 7 kDa RHAMM can be used as a
receptor in developing novel peptide-based ligands that compete with HA for RHAMMbinding.

Figure 2.4. 7 kDa RHAMM binds HA by ELISA. ELISA was performed with HAcoated plates and varying concentrations of biotinylated 7 kDa RHAMM.

2.2.4

Optimization of synthesis

Synthesis of long peptides or short proteins by Fmoc chemistry requires additional
synthetic tools beyond those available through standard Fmoc-based solid-phased peptide
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synthesis. Specifically, aggregation during chain assembly and inter- and intra-chain
interactions can be minimized by special solvents, such as complex solvent mixtures [55],
chaotropic salts[55, 56], structure disrupters such as Pro residues, 2-hydroxy-4methoxybenyl (Hmb) peptide backbone protection [57, 58], and by resins that facilitate
the solvation of peptide chains. Here, we investigate the optimization of 7 kDa RHAMM
by applying pseudoproline dipeptides within its sequence during synthesis, as it has been
advocated as being the most promising method of facilitating the synthesis of long
sequences that are at risk of aggregation [59, 60]. In pseudoproline dipeptides, Ser, Thr,
or Cys residues are reversibly protected as proline-like oxazolidines [60]. As with
proline, the pseudoproline dipeptides induce kinks in the backbone of the growing
polymer chain, thereby removing hydrogen bond donors and disrupting aggregation
during chain elongation. Following completion of synthesis of the peptide, cleavage with
TFA opens the oxazolidine ring, generating the natural amino acid sequence.
While the strategy of using 5-minute microwave irradiation coupling steps in standard
Fmoc-based solid-phase peptide synthesis generated a 62mer mini-protein with high
purity following purification (>95%), the final preparative yield was only a few mg in
total on a 0.05 mmol scale (3%). We therefore tried optimizing the synthesis of the miniprotein by employing pseudoproline dipeptides at various positions within its sequence. 7
kDa RHAMM has 5 Ser resides, 4 of which have commercially available dipeptides
available for replacement: S750, S747, S743, and S708. We evaluated the replacement of the
natural amino acids at each of these sites, and compared their yield and purity with the
normal synthetic strategy of using all L-amino acids (Table 2.1) under identical
synthesis, cleavage and purification conditions.
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Table 2.1. Summary of 7 kDa RHAMM synthesis and purification by SPPS using
natural amino acids and pseudoproline dipeptide on rink amide resin
Pseudoproline substitution

Purity

Preparative
Yield

1

None (all L amino acids, natural sequence)

>95%

3%

2

D707S708

>95%

4%

>95%

10%

>95%

12%

>95%

10%

N742S743
3

D707S708
N742S743
K746S747

4

D707S708
N742S743
V749S750

5

D707S708
N742S743
K746S747
V749S750

Using pseudoproline dipeptides as replacements of two individual amino acids at each of
the positions optimized the synthesis yield for 7 kDa RHAMM from 3% to 12% without
sacrificing purity. The greatest improvement in yield resulted when the amino acids were
replaced at S743 and S750, which lie in the middle of the amino acid sequence and where
aggregation begins to occur. This finding correlates with published protocols, which
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suggest that the effect of pseudoproline dipeptides are realized 6-10 residues after their
incorporation [61, 62]. Interestingly, the replacement of S750, S747, and S743 was less
efficient when compared to the synthesis in which replacement of only S743 and S750 was
done, suggesting that introducing pseudoproline residues at close proximity, and below
the 6-10 residue optimal spacing, negatively influences yield. In this case, a higher than
optimal number of kinks could be introduced in the polymer backbone. Despite the
modest improvement in yield resulting from using the pseudoproline dipeptides, we
concluded that use of natural amino acids is still more prudent for our needs due to the
cost constraints associated with the purchase of commercially available pseudoproline
dipeptides.

2.2.5

In culture functional assay

It has been previously shown that RHAMM regulates cellular functions associated with
motility and affects signaling cascades in mesenchymal cells [26, 27, 63, 64]. RHAMM
blocking antibodies, RHAMM mimetic peptides, and genetic deletion of RHAMM
reduce migration of mesenchymal and other cell types [3, 22, 27, 65-69]. To investigate
whether 7 kDa RHAMM competes with native cell-surface RHAMM on mesenchymal
cells, we quantified scratch wound induced migration of RHAMM-transfected 10T1/2
cells with and without 7 kDa RHAMM. As shown by fluorescent staining, RHAMM is
located in cell processes on the cell surface where it can interact with HA while
intracellular RHAMM is diffused in the cytoplasm (Figure S2.10). 7 kDa RHAMM
inhibited migration of these cells in scratch wound assays, suggesting that it successfully
competes with the endogenous HA receptor for HA binding. (Figure 2.5).
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Figure 2.5. Excisional scratch wound assay performed on RHAMM-transfected
10T1/2 cells (LR21). LR21 cells treated with 7 kDa RHAMM (B) migrate slower
over 24 hours than those not treated with the synthetic receptor (A). Statistical
significance determined by students t-test (***p<0.005). Scale bar, 100 µM.
We have demonstrated that RHAMM binds to HA more tightly than it has been
previously reported to bind to other HA receptors, such as CD44 [70, 71], LYVE-1 [7274]. Interestingly, CD44, which is the major HA-binding receptor expressed on most cell
types [11], appears to require simultaneous clustering with other HA receptor molecules,
including RHAMM, in a multivalent fashion in order to stably bind the polysaccharide
[75]. In addition, the activation of ERK1,2 and cellular motility in culture depend directly
on the function of RHAMM in the presence of HA [27]. In fact, it has been shown that
RHAMM expression increases in response to an increase in the expression of all sizes of
fragmented HA [11], predicting that the development of RHAMM-targeted peptides that
bind and block RHAMM signaling will be useful in blunting many disease processes.
RHAMM regulates cellular functions associated with motility and cellular migration after
injury [27]. The RHAMM mini-protein binds HA and was therefore predicted to act as an
HA fragment sink, inhibiting the normal function of RHAMM. Indeed, this was found to
be the case when RHAMM-overexpressing mesenchymal cells were treated with 7 kDa
RHAMM. LR21 cells are transfected with RHAMM

163

(73 kDa) [76], which differs

from full length RHAMM (RHAMMFL, 85 kDa) in its cellular localization; while both
isoforms of the protein are expressed both intracellularly and at the cell surface, full
length RHAMM localizes primarily to the cytoskeleton and RHAMM

163

has been

suggested to be found primarily in the nucleus, on the cell membrane [77] and at
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podosomes, which are specialized structures of cell substratum contact and matrix
metalloproteinase (MMP) release (Figure S2.10), and therefore, contribute to the
migration. Biotinylated 7 kDa RHAMM was shown by confocal microscopy to be
endocytosed in vesicles by LR21 cells following incubation, with vesicle accumulation in
the perinuclear region (Figure 2.6) as is typical of most endocytosed cell surface
receptors. This is the first report of cells behaving in this manner following treatment
with a RHAMM protein. Treatment of cells with 7 kDa RHAMM protein, despite
truncation to 7 kDa in size, inhibits the natural function of the endogenous cell surface
protein, where it potentially binds endogenous HA receptors or growth factor receptors
that are present at the cell surface, blocking RHAMM-dependent motile behavior.

Figure 2.6. Biotinylated 7kDa RHAMM binds to the cell surface and occurs in
intracellular perinuclear vesicles. The 7kDa RHAMM mini-protein was added to
cultured RHAMM-transfected 10T1/2 fibroblasts, and its distribution was detected
using a fluorescent streptavidin. Results show that extracellular staining can be
detected (solid white arrows) and in intracellular, perinuclear vesicles (dotted white
arrows). Results show that 7 kDa RHAMM is detected near or at the cell surface
and that the majority of staining occurs in perinuclear vesicles, which is consistent
with its endocytic uptake. Blue is Dapi to detect nuclei, and brightfield images are
included to show intact cells.
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2.2.6

Protein-ligand binding studies

We have previously reported the discovery and screening of tubulin-derived peptides that
compete with HA for RHAMM binding by SPR [78]. However, the difficult purification
and isolation of the full-length RHAMM protein renders direct protein-ligand interaction
studies difficult to undertake, and may have hindered the discovery of novel molecules
since. Here, we investigated the interaction between 7 kDa RHAMM and tubulin-derived
peptides by SPR in order to compare chemically synthesized truncated RHAMM with our
previous results using recombinant RHAMM protein.
7 kDa RHAMM was functionalized with a histidine tag on its carboxyl terminus during
synthesis for immobilization on a nitrilotriacetic acid (NTA) biosensor surface without
disrupting the mini-protein’s secondary structure or hindering the HA binding sites.
Previously reported tubulin-derived peptides were observed to bind the immobilized
mini-protein (Figure 2.7) with affinities that are highly comparable to those of the
recombinant protein (Table 2.2), suggesting that truncating the receptor has little effect
on binding potential of RHAMM-binding peptides. Compounds that did not bind the
recombinant protein also showed no binding to the synthesized RHAMM mini-protein,
such as in the case of compound 7a (Figure 2.7). Therefore, the chemically synthesized
receptor appears to be an appropriate replacement receptor for the recombinant protein in
screening novel peptide ligands that bind to the HA binding region of RHAMM.
Interestingly, RHAMM sequence aa706-767 has also been shown to bind to tubulin,
kinases, such as ERK1 [13], and kinase regulators, such as TPX2 [14], suggesting that
this mini-protein will also be useful to screen for peptides that block intracellular
signaling as well as interactions/functions involving microtubules, mitotic spindles and
centrosomes. Successful synthesis of the RHAMM mini-protein permits discovery and
screening for novel RHAMM-binding therapeutic agents, as well as optimizing and
evaluating current HA and RHAMM mimic peptides and other therapeutic agents.
Importantly, this will facilitate the identification of novel drug compounds that block
extra- and intra-cellular RHAMM functions that play important roles in disease
progression.
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Figure 2.7. SPR signals showing the interaction between immobilized 7 kDa
RHAMM and previously reported tubulin-derived peptides, both binding and nonbinding. Negative control (no peptide) graphs are also shown. Each signal
corresponds to the responses of six peptide concentrations (1000 nM, 750 nM, 500
nM, 100 nM, 10 nM, and 1 nM). The solid lines indicate a global 1:1 interaction
curve fitting model for each of the interactions.
Table 2.2. Binding affinities of tubulin-derived peptide analogues for 7 kDa
RHAMM and recombinant RHAMM
Peptide
ID [78]

Conc.

ka

kd

KD

Avg. KD

(nM)

(104/(M*s))

(103/s)

(nM)

(nM)

Avg.
KD
with
recomb.
RHAMM
[78]
(nM)

2b

1000

4.1

0.1

1.6

0.1

39.7

750

5.0

0.1

8.1

0.1

61.5 ± 4.7

500

5.8

0.2

1.4

0.2

72.4 ± 2.3

0.1

43.3

3.7

24.2

0.4

50

3b

10b

11b

12b

100

0.2

0.04

4.3

10

1.6

0.1

1.22

1

0.7

0.1

4.5

1000

1.3

0.1

1.08

0.03

84.3 ± 2.2

750

1.9

0.2

1.03

0.03

54.6 ± 3.3

500

2.3

0.4

0.08

0.02

36.5 ± 1.4

100

1.4

0.1

1.9

0.1

14.3 ± 0.3

10

0.16

0.02

2.4

0.2

1.5 ± 0.2

1

0.02

0.03

5.9

0.2

0.5 ± 0.1

1000

4.0

0.2

1.3

0.1

314.2

12.2

750

3.3

0.1

1.3

0.1

392.1

10.3

500

3.0

0.2

1.1

0.1

366.3

12.3

100

1.4

0.3

1.4

0.2

99.3

12.0

10

2.3

0.2

8.2

0.3

36.3

1.3

1

5.7

0.1

1.5

0.2

2.6

1000

1.6

0.2

2.3

0.3

144.1 ± 15.8

750

1.2

0.1

3.5

0.5

295.2 ± 1.7

500

1.0

0.1

3.9

0.3

379.3 ± 5.8

100

1.5

0.1

0.1

0.2

694.4 ± 5.1

10

0.22

0.02

0.1

0.2

49.3 ± 0.4

1

0.48

0.03

0.1

0.2

29.4 ± 0.5

1000

3.4

0.4

3.1

0.4

90.9

750

2.9

0.2

5.2

0.5

180.2

500

0.9

0.1

7.7

0.6

90.9

100

3.1

0.2

0.8

0.2

476.6

0.1
0.02
0.1

8.8 ± 0.1
77.4 ± 14.8
2.40 ± 0.01
31.9

1.2

331.1 24.5

201.8

8.0

32.6

265.1

4.9

130.0
12.9

289.2

2.2

211.3

1.1

0.2

1.6
3.3
3.7
2.2

8.6
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14b

10

3.1

0.1

0.4

0.1

52.3

1.0

1

3.7

0.12

5.2

0.2

27.0

1.0

1000

2.0

0.3

1.4

0.2

70.7 ± 11.7

750

3.5

0.4

8.5

0.6

23.9 ± 11.1

500

4.9

0.2

8.9

0.7

18.1 ± 7.3

100

0.1

0.1

1.5

0.2

11.3 ± 2.3

10

0.5

0.1

6.2

0.3

1.2 ± 3.1

1

0.8

0.1

1.2

0.2

0.1 ± 0.1

20.9

5.9

30.2

1.5

Conclusion
The present study demonstrated that chemically synthesized truncated RHAMM can be
used as a surrogate for the binding site for screening novel peptide ligands. 7 kDa
RHAMM has the same predicted secondary structure as the native protein [49, 50],
facilitating binding to the native ligand, HA, and is biologically active in fibroblast cells.
Chemical modifications, such as the addition of a histidine tag and a biotin molecule, can
be easily incorporated during synthesis of 7 kDa RHAMM, and purification of the
chemically synthesized mini-protein produces a final compound with higher yield and
purity than is possible for the recombinant protein. In addition, 7 kDa RHAMM binds
previously reported tubulin-derived peptides with similar affinities as recombinant
RHAMM. The high degree of similarity in binding kinetics between the tubulin-derived
peptides and recombinant RHAMM and the peptides and chemically-synthesized
RHAMM is suggestive of a strong similarity in the binding action of the two proteins.
Therefore, 7 kDa RHAMM may have potential applications in further characterizing the
nature and functions of the interactions of RHAMM with HA and other ligands, which
are currently lacking in the literature. For these reasons, 7 kDa RHAMM is an efficient
and effective replacement receptor protein for screening and discovering novel RHAMMbinding ligands, and will allow for the specific inhibition of RHAMM-ligand
interactions, and treatment of RHAMM-associated diseases.
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Experimental
2.4.1

General Methods

All peptides, 7 kDa RHAMM, and modified versions of the mini-protein containing
pseudoproline dipeptides and a C-terminal histidine tag, were synthesized on an
automated synthesizer (Syrowave, Biotage) applying fluorenyl-9-methoxycarbonyl
(Fmoc) solid phase peptide synthesis. All coupling reactions were carried out under
microwave conditions at 75 C for 5 minutes with vortexing, with the exception of
histidine residues, which were double coupled for 90-minute and 30-minute intervals at
room temperature. Cleavage of the peptides was carried out by treating the resin with
TFA: water: triisopropylsilane (95:2.5:2.5 v/v) for 5 hours. The cleaved peptides were
then precipitated with cold TBME, and were pelleted by centrifugation at 1000 Gs for 10
min. After decanting the supernatant, the pellets were rinsed with tert-butyl methyl ether
(TBME), re-suspended by vortexing, and centrifuged again. The ensuing products were
dissolved in water, frozen and lyophilized until a dry, solid powder was obtained.
Analysis of the peptides was carried out using a reversed-phase analytical HPLC column
(Agilent Zorbax SB-C18 column 4.6 x 150 mm, 3.5 m). This system was outfitted with
a Waters 600 136 controller, Waters Prep degasser, and Waters MassLynx software
(version 4.1). The mobile phases employed were 0.1% TFA in water (solvent A) and
0.1% TFA in acetonitrile (solvent B) with a flow rate of 1.5 mL/min over 15 minutes.
The absorbance was monitored using a Waters 2998 Photodiode array detector set at 220
nm, 254 nm, and 400 nm. All peptides and 7 kDa RHAMM were purified using a
reversed-phase preparative HPLC column (Agilent Zorbax SB-C18 column 21.2 x 150
mm, 5 m) all system specifics were the same as those used for the analytical system.
The flow rate for the preparative HPLC was set at 20 mL/min, with the absorbance being
monitored under the same conditions as previously described. The collected fractions
were then lyophilized to a solid, and subsequently analyzed by analytical RP-HPLC (220
nm) and ESI-MS on a Acquity UHPLC-MS system (Waters Co.).
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2.4.2

Synthesis and purification of 7 kDa RHAMM

Synthesis was conducted on a 0.05 mmol scale using Rink amide MBHA (0.39 mmol/g),
with a four-fold excess of Fmoc protected L-amino acids. Amino acids were coupled with
HCTU (4 eq.) in DMF and DIPEA (6 eq.). All couplings from Ser30 onwards were double
coupled. Fmoc was removed using 2 treatments of 20% piperidine/DMF for 15-minute
and 5-minute periods. Following synthesis, the resin was washed with dichloromethane.
Purification of 7 kDa RHAMM was carried out as described above at a gradient of 25 to
45%.

2.4.3

Circular Dichroism spectroscopy

CD was carried out on a Jasco J-810 spectropolarimeter and recorded in the range of 180260 nm. 7 kDa RHAMM (>95% purity, lyophilized) was dissolved in Milli-Q water to a
concentration of 0.5 mg/mL. The measurement was carried out at 20 ᴼC, using a quartz
cuvette with a path length of 1 mm. The instrument measured at a scanning speed of 1050 nm/min, and averaged five individual data points in order to obtain the reported CD
spectrum. A blank solution of Milli-Q water, and 40% TFE/water were run before the
measurements, and the spectra were baseline corrected.

2.4.4
2.4.4.1

Evaluation of HA-binding
SPR

5-10kDa HA (purchased as sodium hyaluronate, Research Grade 5K, Lifecore
Biomedical) was dissolved in DMSO/H2O (7/3, v/v), and was reacted with excess sodium
cyanoborohydride for 12 hours at room temperature. 10 equivalents of cysteamine
hydrochloride (Sigma Aldrich) was added, and the reaction proceeded for an additional
24 hours. The solution was then dialyzed exhaustively in deionized water for 3 days
using a 3.5-5 kDa dialysis tube (Float-a-Lyzer, Spectrum Labs) with a biotech grade
cellulose ester membrane.
All experiments were carried out on an OpenSPRTM instrument (Nicoya Lifesciences) at
25 C, equipped with a 100 L loading loop. 100 nm gold nanoparticle biosensors were
purchased from Nicoya Lifesciences. All experiments were carried out in phosphate
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buffered saline (PBS) running buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2
mM KH2PO4), pH 7.4. The gold biosensors were incubated with cystaminefunctionalized 5-10 kDa HA (3mg/mL) for 3 days. Available binding sites on the chip
surface were blocked with poly(ethylene glycol) methyl ether thiol (2 mg/mL) (Sigma
Aldrich). 7 kDa RHAMM and Ala-7 kDa RHAMM were dissolved in PBS at varying
concentrations, and were injected at a flow rate of 25 L/min when the baseline was
stabilized. Regeneration of the chip surface was carried out with 1M NaCl, and no further
injections were done until the baseline was stable. The data was processed and analyzed
using Tracedrawer software (Ridgeview Instruments AB). Kinetic parameters were
calculated using a local analysis, fitting the data to a 1:1 model.

2.4.4.2

ELISA

Biotinylated 7 kDa RHAMM was synthesized under the same conditions as before, but
was N-terminally modified to include biotin as the free acid (Sigma Aldrich), separated
by a PEG-2 linker from the remainder of the mini-protein strand. Fmoc-AEEA-OH
(PEG-2) (3 eq.) was coupled onto the N-terminus of the peptide at room temperature for
1 hour with activation by HCTU (3 eq.) and DIPEA (6 eq.). Following Fmoc
deprotection with two cycles (5 minutes and 15 minutes) of 20% piperidine in DMF,
Biotin-OH (3 eq.) was added with HATU (3 eq.) and DIPEA (6 eq.), which proceeded
overnight. Cleavage of the truncated protein from the resin was carried out as described
above. 7 kDa RHAMM was purified by the same method as before, with a solvent
gradient of 30 to 45%.
An ELISA was utilized to measure HA-binding. Five milligrams of biotin-labeled miniprotein was dissolved in 1 mL phosphate-buffered saline (PBS). This stock solution was
further dissolved in 1X Tris-buffered saline (TBS) to generate peptide solutions of 50
μg/mL, 10 μg /mL, 2 μg /mL, 0.4 μg /mL, 0.08 μg /mL, and 0.016 μg/mL. These were
subsequently added to HA coated ELISA plates (200 μL/well, triplicates, Echelon kit K1200), and were incubated overnight at 40 °C. 200 μL of 1X TBS was used as a negative
control. Wells were washed 3 times with 200 μL 1X TBS and then 100 μL pre-diluted
streptavidin-HRP (LSAB2 Streptavidin-HRP, DAKO K1016) was added to each well and
the ELISA plate was incubated for 1 hour at room temperature. Wells were washed 3
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times with 200 μL 1X TBS and 100 μL 3,3’,5,5’-tetramethylbenzidine (TMB) solution
(Echelon kit K-4800) was added. After a 20-minute incubation at room temperature, 50
μL 1N H2SO4 stop solution was added. Absorbance was measured at 450 nm using a
SYNERGY H4 (BioTek) plate reader. Data was fitted to a nonlinear regression curve
with equation Y = 0.97 + (0.07 - 0.97)e-2.58X.

2.4.5

Optimization

All syntheses were carried out as described above, except that Fmoc-Asp(OtBu)Ser(

Me,Me pro)-OH,

Fmoc-Asn(Trt)-Ser(

pro)-OH, and Fmoc-Val-Ser(

Me,Me pro)-OH,

Me,Me pro)-OH

Fmoc-Lys(Boc)-Ser(

Me,Me

(Novabiochem) were used to introduce

D707S708, N742S743, K746S747, and V749S750, respectively. All coupling reactions were
carried out under the same conditions as their L-amino acid counterparts. Cleavage of the
peptides from the resin, and purification were carried out as before.

2.4.6

Confocal Microscopy

LR21 cells were plated on fibronectin coated cover slips. The next day, medium was
changed to defined medium (DEMEM, insulin, transferrin) and 10 M biotinylated 7
kDa RHAMM was added. Defined medium without biotinylated 7 kDa RHAMM was
used as negative control. After 24 hrs, cover slips were washed three times with 1X PBS.
Cover slips were treated with 0.1 % Triton-x /PBS for 10 min at RT, then washed once
with 1X PBS. Cover slips were blocked with 3% BSA/PBS for 1 hour at RT. Blocking
buffer was removed and fluorescent streptavidin (Alexa 647), diluted 1:250 in 1%
BSA/PBS, was added. After 2 hours at RT, cover slips were washed three times with 1X
PBS at RT, then cover slips were mounted with mounting medium containing DAPI
(Invitrogen, antifade Gold with DAPI). A confocal microscope (Olympus) was used to
obtain fluorescence and DIC images using a 100X objective.

2.4.7

Scratch Wound Assay

LR21 cells were cultured in DMEM low glucose medium containing 10% FBS and
antibiotics/antimycotics. For scratch wound assays, sufficient LR21 cells were plated in
fibronectin (25 g/ml PBS) coated ibidi 15 -slide 8 well chambers to allow formation of
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a confluent cell monolayer. The next day, cultures were scratch wounded using a blue
micro pipettor tip. Cells were washed once with growth medium to remove cell debris.
Medium was changed to defined medium (DMEM low glucose, 4 g/ml insulin, 8 g/ml
transferrin, antibiotics/antimycotics) containing 7 kDa RHAMM (1 M). 8 well
chambers were placed inside an ibidi environmental chamber attached to an ibidi
temperature controller and gas mixer. Culture conditions were kept constant at 37 ºC, 5%
CO2, humidified atmosphere. Wound closure was filmed for 24 hours using a Nikon
Eclipse TE 300 microscope equipped with a 10X objective, Hoffman optic and a
Hamamatsu digital camera. Image acquisition occurred every 5 min over 24 hours and
was controlled by NIS-Elements AR 3.2 software. Wound closure was quantified by
measuring migration distance of the migration front over 24 hours using the NISElements AR 3.2 software.

2.4.8

Statistical Analysis

Statistical analysis was performed using GraphPad Prism® software. Data were
expressed as means ± SEM. Statistical analysis was performed using a one-way ANOVA
and Tukey’s post-hoc test with level of significance indicated as follows: *p < 0.05, ** p
< 0.01 and *** p < 0.001

2.4.9

SPR experiments with tubulin-derived peptides

Histidine tagged 7 kDa RHAMM was synthesized by first synthesizing the histidine tag
on the C-terminus, comprising of six His residues, which were coupled at room
temperature. Following synthesis of the His tag, Fmoc-AEEA-OH (PEG-2) (3 eq.) was
coupled, followed by the synthesis of 7 kDa RHAMM, which was synthesized under the
same conditions as before. Cleavage of the peptide from the resin was carried out as
before. 7 kDa RHAMM was purified by the same methods as described above, with a
gradient of 25 to 45%.
All experiments were carried out on an OpenSPR

instrument (Nicoya Lifesciences).

Nitrilotriacetic acid (NTA) biosensors were purchased from Nicoya Lifesciences. All
experiments were carried out in PBS buffer. The sensor chip surface was primed with
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imidazole (200 mM) and NiCl2 (40 mM). 7 kDa RHAMM was immobilized onto the
biosensor surface at a flow rate of 25 L/min using a protein concentration of 0.1 mg/mL
in a 100 L sample loop. The peptide ligands were dissolved in water at 10X, 4X, 2X,
and 1.25X concentration dilutions from 1 mM to 100 pM, and were injected at a flow rate
of 25 L/min when the protein signal was stabilized. Regeneration of the chip surface
was carried out with 1 M NaCl, and no further injections were done until the baseline was
stable. The data was processed and analyzed using Tracedrawer software.

2.4.10

Immunofluorescent staining

10T1/2 cells were purchased from ATCC and transfected with 73 kDa RHAMM and a
full-length RHAMM cDNA encoding either Zs-green or non-immune IgG [76]. For
immunofluorescent staining, RHAMM-transfected cells were plated on fibronectincoated coverslips. The confluency of these cultures was less than 50%. Cells were fixed
in 4% paraformaldehyde/PBS pH 7.5 for 10 minutes at RT. Fixed cells were washed two
times with PBS. Non-specific antibody binding was prevented by incubating cover slips
with 3% BSA/PBS for 1 hr. Cover slips were then incubated with either a primary
antibody to ZsGreen (CloneTech) or non-immune IgG used as a negative control
according to manufacturer’s instructions. Cover slips were washed three times with PBS
to remove unbound IgG/antibody and were then incubated with Alexa dye-conjugated
secondary antibody (Alexa 555 or Alexa 488, Invitrogen), washed and mounted using
DAPI containing ProLong Gold antifade mounting reagent (Invitrogen). Cells were
imaged using a confocal microscope (Olympus IX81) using FV10-ASW 4.2 software.
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Figure S 2.11. ESI+ Mass Spectrum for 7 kDa RHAMM
AHK-06-109-Ala-RH-qc22-25-20to80-2 1117 (1.436) Cm (1103:1149)
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Table S 2.1. Calculated and observed m/z peaks of 7 kDa RHAMM
m/z calculated

m/z observed

[M+5H]5+

1446.55

1446.47

[M+6H]6+

1205.59

1205.63

[M+7H]7+

1033.88

1033.78

[M+8H]8+

904.39

904.45

[M+9H]9+

804.15

804.12

[M+10H]10+

723.72

723.77

[M+11H]11+

658.11

658.09

[M+12H]12+

603.20

603.23

Table S 2.2. Calculated and observed m/z peaks of Ala-7 kDa RHAMM
m/z calculated

m/z observed

[M+4H]4+

1651.89

1562.02

[M+5H]5+

1321.71

1321.94

[M+6H]6+

1101.60

1101.65

[M+7H]7+

944.37

944.39

[M+8H]8+

826.45

826.62
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Table S 2.3. Calculated and observed m/z peaks of tubulin-derived peptides
Peptide

Peptide Sequence

Mmono
calculated

Mmono
observed

m/z
calculated

m/z
observed

Purity
(%)

2b

H-VEGEGEEEGEEY-NH2

1353.52

1358.28

677.77

677.56

>92

3b

H-SVEAEAEEGEEY-NH2

1339.53

1339.30

670.77

670.66

>95

10b

H-EEDFGEEAEEEA-NH2

1381.51

1381.28

691.76

691.65

>95

11b

H-GEFEEEAEEEVA-NH2

1365.55

1365.39

683.78

683.70

>94

12b

H-EAFEDEEEEIDG-NH2

1409.54

1409.56

705.33

705.79

>93

14b

H-FTEAESNMNDLV-NH2

1367.60

1368.08

684.81

684.43

>94

7a

H-GEFSEAREDMAA-NH2

1310.55

1311.44

656.28

656.73

>97

ID [49]

ZP-150608-01-0015A1-2 5-20B 72 (1.343) Cm (71:72)

1: TOF MS ES+
56

%

100

677.7338
86.1054

171.0917

677.6677

678.2123
678.7407

0

100

200

300

400

500

600

700

1354.9600

800

900

1000

1100

1200

1300

1400

1500

1600

1700

1800

1900

2000

m/z
2100

Figure S 2.13. ESI+ Mass Spectrum for Peptide 2b (H-VEGEGEEEGEEY-NH2)

74
ZP-150810-15H-Pr2-2 5-40A 58 (1.082) Cm (57:59)
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Figure S 2.14. ESI+ Mass Spectrum for Peptide 3b (H-SVEAEAEEGEEY-NH2)
ZP-150727-15F P1b 5-40A 68 (1.269) Cm (68:70)
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Figure S 2.15. ESI+ Mass Spectrum for Peptide 10b (H-EEDFGEEAEEEA-NH2)
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Figure S 2.16. ESI+ Mass Spectrum for Peptide 11b (H-GEFEEEAEEEVA-NH2)
ZP-150615-01-015D 5-40A 76 (1.419) Cm (76)
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Figure S 2.17 ESI+ Mass Spectrum for Peptide 12b (H-EAFEDEEEEIDG-NH2)
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Figure S 2.18. ESI+ Mass Spectrum for Peptide 14b (H-FTEAESNMNDLV-NH2)
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Chapter 3

3

The Development of RHAMM Peptide Mimetics for
Blocking Inflammation
Introduction

Hyaluronan is a nonsulfated, linear glycosaminoglycan (GAG) that is composed of
repeating disaccharide units of (ß, 1-4) glucuronic acid (GlcUA) and (ß, 1-3) Nacetylglucosamine (GlcNAc). In homeostatic tissues, native HA is a polysaccharide that
has a high molecular weight (HMW) of >500 kDa. Native HMW HA is the major
carbohydrate component of the extracellular matrix (ECM) in all tissues, where it acts to
maintain water homeostasis and matrix structure [1], and as such, plays a vital role in
tissue organization and cellular behaviour, including proliferation, growth, and motility
[2-8]. However, like many other components of the ECM, HMW HA is broken down to
oligosaccharide fragments by hyaluronidases (HYALs) and free radicals (reactive
oxygen/nitrogen species, ROS/RNS) in response to cellular stresses, resulting in the
accumulation of lower molecular weight (LMW) forms of the polysaccharide that have
different functions than their native HMW precursors [9-13]. Many of HA’s functions
appear to be mediated through specific HA receptors, including LYVE-1, Stab2, CD44
and receptor for hyaluronan mediated motility (RHAMM/HMMR/CD168). Fragmented
HA-HA receptor interactions have been shown to increase inflammation, fibrosis and
angiogenesis, all of which are processes that have the potential to lead to development of
disease.[11, 13-16]. In the case of inflammation specifically, their increased interaction
activates macrophages and the expression of pro-inflammatory genes and cytokines, such
as macrophage chemoattractant protein-1 (MCP-1), Interleukin-8 (IL-8), RANTES, and
TNF- [17]. A positive feedback loop is also possible when an HA-induced
inflammatory response perpetuates further inflammatory processes; inflammation leads to
inflammation, and this may eventually lead to fibrosis [7]. Thus, scavenging HA
fragments, and preventing HA fragment-HA receptor interactions with targeted entities
has both a preventative and therapeutic application.
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RHAMM is unique among the group of HA receptor proteins in its strong binding
affinity and specificity for HA (Hauser-Kawaguchi, et al., submitted). In addition, unlike
the other HA receptors, which bind HA through a link module binding motif [18],
RHAMM binds HA through two HA binding domains, both of which have a BX7B
binding motif, where B represents a basic amino acid, and X represents any non-acidic
amino acid [19]. Further, RHAMM binds directly to microtubules [20, 21] and
TPX2/AURKA A [22, 23] through the leucine zipper that exists between the two HA
binding domains. RHAMM is largely present in the cytoplasm and nucleus, where its
expression is tightly regulated [24-26], but is also exported to the cell membrane by
unconventional mechanisms in response to cellular stress, where it associates with
transmembrane receptors including CD44 and PDGFR in order to activate ERK 1,2 [20,
27-29] and focal adhesion kinase (FAK) [30] signaling pathways. The exact signal
transduction mechanism of RHAMM-HA-induced signaling has not yet been fully
characterized.
Several RHAMM mimetic peptides have been reported to have functional properties [30,
31]. Here, we report the design and synthesis of the first cyclized RHAMM peptide
inhibitors and show that this strategy is effective for targeting HA fragments and
blocking HA fragment-induced signaling outcomes. Specifically, these RHAMM
mimetics have been stabilized by two lactam bridge staples that are adjacent to one
another, which we have shown facilitate ligand binding, and therefore, bioactivity both in
culture and in vivo, suggesting that they have therapeutic potential in treating
inflammation-related diseases.

Results and Discussion
The development of peptide mimetics that bind to HA fragments has proven successful as
a therapeutic approach in experimental models of inflammation and other diseases. These
peptides bind directly to and sequester HA fragments, which are therefore prevented from
binding and activating receptors.
We have developed 30mer RHAMM peptide mimetics that incorporate both HA binding
domains of RHAMM as well as the linker region that connects them. Our aim was to
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develop peptides that have improved affinity towards their target HA, resulting in
improved efficiency for scavenging HA, and therefore, are more effective at blocking HA
fragment-induced signaling in culture and in vivo.
We have identified RHAMM peptide mimetics that have been stabilized by the insertion
of lactam bridge staples in the portion of the peptide sequence that lies between the two
HA binding domains. We propose that these peptides are prototypical drug molecules,
especially our lead compound, Peptide 3.1, and its variants, which may be used for the
treatment of conditions that arise from HA signaling, especially those that involve a
strong inflammatory response, such as pro-inflammatory conditions and some cancers.
RHAMM has been reported to be a largely helical protein, and specifically, the two HA
binding domains have been reported to have helical character. It has been hypothesized
that the arrangement of the binding domains in this structure facilitates the correct
orientation of the basic residues in the BX7B binding motif towards the target so that the
two molecules will interact [32]. To this end, two adjacent (i, i+4) lactam bridge staples
were inserted between the two HA binding domains in order to stabilize the linker region
and confer further helicity to the shortened RHAMM peptides. In addition, we
investigated whether the order of amino acids forming the lactam bridge was important
for HA binding, as it has been reported that staples formed by a Lys-Glu staple were less
efficient in improving helicity over the Glu-Lys counterpart [33].
In order for the RHAMM peptide mimetics to prevent the activation of signaling
pathways, they are required to target and scavenge HA fragments. As expected, all of the
compounds bound to HA, as they contain the HABDs, which are required for ligand
binding. However, the improvement in ligand-binding observed in the cyclized peptides
is noteworthy. Cyclization significantly improved the affinity of these compounds for HA
compared to the linear peptide in all cases, as well as decreased their dissociation from
HA, suggesting that the double stapled peptides are more specific for their target than
their linear counterpart. The most notable increase resulted in the case of Peptide 3.1, in
which both staples were formed by the conjugation of the side chains of an N-terminal
Glu and C-terminal Lys residue. Interestingly, switching the order of staple-forming
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residues decreases the compound’s binding affinity for the ligand (Peptides 3.3 and 3.4).
Because the sequence or placement of the staples does not vary between Peptide 3.1 and
Peptides 3.3 and 3.4, the difference in binding affinity is likely due to the difference in
secondary structure of the overall compound, where improved helicity results in
improved HA-binding. This insertion and placement of the staples confers rigidity into
the structure, cyclizing the linker region of the peptide, ensuring that the HABDs are
accessible to the ligand.
Table 3.1. Sequences of double stapled RHAMM peptide mimetics and their linear
counterpart. Side-chain cyclization indicated by square brackets.
Peptide ID

Sequence

Linear

Ac-KIKHVVKLKDENSQLKSEVSKLRSQLVKRK-NH2

3.1

Ac-KIKHVVKLK[EENSK][EKSEK]SKLRSQLVKRK-NH2

3.2

Ac-KIKHVVKLKD[ENSQK][ESEVK]KLRSQLVKRK-NH2

3.3

Ac-KIKHVVKLK[EENSK][KKSEE]SKLRSQLVKRK-NH2

3.4

Ac-KIKHVVKLK[KENSE][EKSEK]SKLRSQLVKRK-NH2

3.2.1 CD Spectroscopy
The importance of the secondary structure of RHAMM’s HABDs is a well-accepted
characteristic for the ligand binding to the receptor [32, 34, 35]. We evaluated the
secondary structure of each of the peptides by CD spectroscopy, and determined the
mean residue ellipticity of the peptides by taking the ratios of the values at the two
minima that are characteristic of an alpha-helix, 208 and 222 nm. The closer the ratio
approaches a value of 1, the closer the peptide achieves perfect helicity, while a greater
value at 208 nm than at 222 nm suggests the presence of additional conformations in the
structure, such as some beta sheet or random coil properties [36]. The secondary structure
of the linear peptide was observed to have a mean residue ellipticity of 0.32 in water,
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suggesting some degree of alpha-helical character, which improved to 0.80 in a 40% TFE
solution, following stabilization of the compound’s inherent secondary structure [37]. All
of the double stapled peptides were reported to exhibit an increase in helicity compared to
their linear counterpart. The peptide with the highest degree of helical character was
Peptide 3.1.
The availability of the RHAMM binding domains in the correct conformation is a
requirement for binding of the receptor to the ligand. Therefore, some alpha-helical
character observed in the linear peptide, which contains both HABDs, is expected, but the
minimal degree of helicity is the result of a lack of hydrophobic residues that would
contribute to a hydrophobic core [35]. Cyclization of the peptide backbone is a
commonly used technique that decreases the flexibility and free rotation of individual
bonds contained within the staple, as well as facilitates the distinct formation of an alphahelical secondary structure. Thus, the addition of staples in the peptide backbone within
the linker region acts to stabilize the inherent helicity present within the peptide
sequence, evidenced by the linear peptide, and identify those compounds with the
greatest potential for targeting HA fragments and preventing HA signaling.
Table 3.2. Mean residue ellipticities of linear and double stapled peptides at 0.25
mg/mL of peptide
Peptide ID

Water [θ]222 /[θ]208

Water + 40% TFE [θ]222 /[θ]208

Linear

0.32

0.80

3.1

0.65

0.85

3.2

0.48

0.83

3.3

0.37

0.83

3.4

0.41

0.81
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Figure 3.1. Stapling RHAMM peptide mimetics increases helicity compared to the
linear peptide by CD spectroscopy in both water (A) and 40% TFE solution (B)

3.2.2

Cyclized RHAMM peptide mimetics bind hyaluronan with
high affinity

All of the peptides were evaluated for their binding to LMW HA fragments (5-10 kDa).
Cystamine-functionalized HA [38] was covalently conjugated to a gold nanoparticle
surface, providing a biosensor for SPR experiments. PEG thiol was used to block any
available sites on the chip in order to prevent nonspecific binding of the peptides to the
gold surface (data not shown).
All of the peptides were observed to bind to the 5-10 kDa HA surface over a range of
peptide concentrations, including the linear peptide. All of the double stapled peptides
(3.1 – 3.4) had improved binding to HA over the linear peptide, as well as a slower
dissociation rate. Peptide 3.1 had the strongest binding to HA, binding the ligand with a
KD of 88 nM, and was found to have the slowest dissociation from the HA surface.
Table 3.3. Kinetic analysis of linear and double stapled peptides
Peptide ID

Average ka
(103/(M*s))

Average kd
(10-4/s)

Average KD
(nM)

Linear

2.6

0.1

3.4

0.3

1260.2

3.1

5.3

0.2

4.7

0.5

88.5

6.3

3.2

7.0

0.4

1.7

0.7

240.3

16.4

3.3

7.6

0.8

1.4

0.8

168.4

21.1

3.4

6.1

0.5

1.4

0.4

230.6

13.8

24.8
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Figure 3.2. SPR signals of linear and stapled peptides. Stapling and staple placement
are important for HA-binding. Each signal corresponds to the response of 5 peptide
concentrations (750 nM, 1 M, 2.5 M, 5 M, and 10 M). The solid lines indicate a
global 1:1 interaction curve fitting model for each of the interactions.

3.2.3

Cyclized RHAMM peptide mimetics block inflammation

RHAMM expression is induced in macrophages following tissue injury or cellular stress,
so blocking normal RHAMM function in sites of injury would reduce the RHAMMmediated inflammatory response. Several approaches have been reported for blocking
pro-inflammatory signaling that is mediated by HA fragments, including, but not limited
to inhibiting HA synthesis by small molecules, such as 4-MU [39, 40], gene knockdown
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or knockout [41-43], blocking hyaluronidase production, and with targeted peptides that
bind either HA or HA receptors [30, 31, 44, 45]. Here, we discuss and validate the first
RHAMM-based cyclized peptides for treating inflammation. Other HA-targeted peptides
have been developed and shown to have therapeutic potential in inflammation, wound
repair, and fibrosis/adipogenesis models [31], and as such, this class of molecule offers
considerable promise in regulating inflammation-based diseases and disorders.
The lead peptide was subjected to an inflammation protein array to determine the specific
cytokines that would be the best readout to measure bioactivity of our peptide library.
The mouse inflammation array was purchased from R&D Systems and performed
according to manufacturer’s protocol. Briefly, RAWBlue macrophages were stimulated
with Toll-like receptor (TLR) agonist PAM3CSK4 to induce inflammation and treated
with peptide at the same time for a period of 24 hours. The peptide was found to block
the expression of a number of inflammatory cytokines measured in the array, the most
notable of which was RANTES, where the peptide was able to bring the levels down
close to that of the control (Figure 3.3).

Figure 3.3. An inflammation protein array was performed on RAWBlue
macrophages stimulated with TLR agonist PAM3CSK4 in the presence or absence
of 1 M of peptide
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Peptide 3.1 was further validated in vivo where it blocked 54% of tumor necrosis factor
alpha (TNF- ) levels under pro-inflammatory conditions following exposure to
lipopolysaccharide (LPS) (Figure 3.4). By blocking cytokine recruitment in vivo, we
have shown that our lead compound could potentially be used to prevent fragmented HAmediated signaling, including macrophage recruitment.

Figure 3.4. Preclinical evaluation of Peptide 3.1 was carried out in mice that were
stimulated with lipopolysaccharide (LPS), a TLR agonist. Preliminary results
demonstrate that a 54% decrease in TNF- concentration is observed in the
presence of Peptide 3.1 compared to the LPS.
In order to compare the effects of the stapled peptides, Peptides 3.1-3.4 and their linear
counterpart were evaluated for their ability to block inflammation in a RANTES ELISA
at a single concentration of 50 nM, which was determined from a dose response of
Peptide 3.1 (data not shown). All of the stapled peptides were observed to block the
RANTES expression more effectively following stimulation with PAM3CSK4 than the
linear peptide, which was not found to block the cytokine’s expression at all.
RHAMM functional peptides have been developed and successfully been shown to block
cellular functions based on the HA-RHAMM interaction, and have therapeutic effects in
a number of processes, including inflammation, wound repair, and adipogenesis, without
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conferring any observable negative toxicities in the injected tissues [31, 46], suggesting
that other RHAMM peptide mimetics have a wide range of potential therapeutic
applications. Moreover, RHAMM R3 vaccines have already been tested in Phase I/II
clinical trials [47, 48], offering promise that other RHAMM-based therapeutics can be
developed and safely translated to a clinical setting.
Table 3.4. Inhibition of RANTES expression (compared to +PAM3CSK4 positive
control) was observed in response to a number of peptide variants (50 nM dose).

3.2.4

Peptide ID

Inhibition (at 50 nM)

Linear

0%

3.1

27%

3.2

11%

3.3

10%

3.4

0%

Cyclization improves peptide stability

Peptide stability was evaluated by monitoring the degradation of the compounds
following incubation in human serum. In addition to improving helicity, peptide stapling
increases the diameter of the compound so that it exceeds that of the protease active site,
and reduces exposure of the vulnerable amide backbone to protease cleavage [37, 49].
Thus, we expected that the stapled peptides would have improved resistance to enzymatic
breakdown than their linear counterpart. In a similar fashion, N-terminal acetylation and
carboxyamidation increase a peptide’s resistance to enzymatic breakdown, and
specifically hinders the actions of exopeptidases and endoproteases [50]. As expected, the
linear peptide degraded at a much faster rate than all of the cyclized variants, with
degradation occurring immediately after incubation in serum began (Figure 3.5).
Interestingly, all of the stapled peptides were still >80% intact after 6 hours of incubation,
while the linear peptide had only 11% of the peptide remaining. The most notable
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degradation product in all of the stapled peptides, particularly after 24 hours of
incubation, correlated with the loss of the first three N-terminal residues of the peptide
sequence, KIK. No other cleavage products were observed, suggesting that the remainder
of the peptide remains intact over the 24-hour incubation period. The residues being
cleaved belong to the first HABD (HABD1) of the RHAMM protein (mRHAMM 721750), which has predicted by computational modeling to be less important for HA
binding [35]. The first HABD comprises fewer leucine and glutamine residues in its
primary sequence than that of the second HABD, and these amino acids have been
proposed to have a greater propensity to form an alpha-helix, making them helixinducing and stabilizing residues [51]. With fewer helix-stabilizing residues in its
sequence, HABD1 may not only have less helical character than HABD2, but may also
contribute less to the overall stability of the compound, and therefore, be more likely to
produce degradation products following incubation in serum.
Table 3.5. Peptide stability in 25% human serum at 6 hours and 24 hours
Peptide ID

Percent remaining after 6 hours

Percent remaining after 24 hours

Linear

11.4 ± 3.3

0.3 ± 0.1

91.7 ± 7.4

1.9 ± 0.1

3.1
3.2
3.3
3.4

82.3 ± 6.8
86.5 ± 4.1
66.6 ± 6.3

4.7 ± 0.7
23.1 ± 0.1
4.2 ± 2.1
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Figure 3.5. Stapling the peptide backbone (black) increases the half-life in human
serum compared to the linear (red). Data was fit to nonlinear regression curves.

3.2.5

Modifying the lead compound to find a metabolically stable
compound with strong binding affinity

The effect of altering the rigidity of the linker region was evaluated by removing the
adjacent double staple. If two adjacent staples confer rigidity, removing one, or inserting
a linker to separate them should increase the flexibility of the region, and therefore,
destabilize the helical structure. Peptide 3.1 was used as a model for determining the
effect of specific modifications to the structure and sequence on helicity and binding
affinity. We evaluated the effect of removing the three N-terminal residues, KIK, which
were observed as cleavage products following incubation in serum (Peptide 3.1-KIK), as
well as that of destabilizing the linker region between the two HABDs. In addition, we
studied the effect following staple separation by one residue (3.1+Gly), two residues
(3.1+GG), helix-inducing residues (3.1+AA), a hydrophobic residue, N-aminomethyl
benzoic acid (amb) (3.1+amb), and the isolation of one of the staples, either the first
staple (3.1_1st staple) or the second staple (3.1_2nd staple).
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Table 3.6. Modifications to the linker region of Peptide 3.1. (*Peptides named based
on IUPAC-IUB Joint Commission on Bicohemical Nomenclature [52], but reference
ID will be used for ease of reference.)
Peptide ID

Reference ID* Sequence

3.1

3.1

Ac-KIKHVVKLK [EENSK]-[EKSEK]
SKLRSQLVKRK-NH2

des-(K1-K3)-Peptide 3.1

3.1-KIK

Ac-HVVKLK [EENSK]-[EKSEK]
SKLRSQLVKRK-NH2

[Leu16,Val20]-Peptide 3.1

3.1_1st staple

Ac-KIKHVVKLK [EENSK]-LKSEV
SKLRSQLVKRK-NH2

[Asp10,Lys14]-Peptide 3.1

3.1_2nd staple

Ac-KIKHVVKLK DENSQ-[EKSEK]
SKLRSQLVKRK-NH2

endo-Gly15a-Peptide 3.1

3.1+Gly

Ac-KIKHVVKLK [EENSK]-Gly[EKSEK] SKLRSQLVKRK-NH2

endo-Amb15a-Peptide 3.1

3.1+Amb

Ac-KIKHVVKLK [EENSK]-Amb[EKSEK] SKLRSQLVKRK-NH2

endo-Gly15a, Gly15b-

3.1+GG

Peptide 3.1
endo-Ala15a, Ala15b-

[EKSEK] SKLRSQLVKRK-NH2
3.1+AA

Peptide 3.1
des-(K1-K3)-endoAla15a, Ala15b-Peptide 3.1

Ac-KIKHVVKLK [EENSK]-G-G-

Ac-KIKHVVKLK [EENSK]-A-A[EKSEK] SKLRSQLVKRK-NH2

3.1-KIK+AA

Ac-HVVKLK [EENSK]-A-A-[EKSEK]
SKLRSQLVKRK-NH2

We observed a significant difference in secondary structure in the modified 3.1-series
peptides in a solution without the secondary structure-stabilizing solvent, TFE. In the
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cases of 3.1_1st staple, 3.1+Amb, 3.1+Gly, and 3.1+GG, the peptides not only lost some
of their helical character, but may have even started to gain random coil character.
Peptide 3.1_2nd staple has greater alpha-helical character compared to those that appear
to have random coil properties. This is particularly interesting when compared with
3.1_1st staple, as the stark difference in helicity between the two peptides is attributed to
the position of the staple. In 3.1_1st staple, the staple is placed adjacent to the first
HABD, while in 3.1_2nd staple, the staple is placed adjacent to the second HABD, which
has been reported to have greater helical character than the first, as well as play a greater
role in HA binding than the first based on computational modeling [35] and site
mutagenesis analysis [19]. This is further supported by the similar helicities observed
between Peptide 3.1 and Peptide 3.1-KIK, in which three residues were removed from
HABD1, suggesting that the entirety of HABD1 does not contribute to RHAMM’s
overall helicity, and therefore, potentially does not bind to HA.
Table 3.7. Mean residue ellipticities of 3.1-series peptides
Peptide ID

Water [θ]222 /[θ]208

Water + 40% TFE [θ]222 /[θ]208

3.1

0.65

0.85

3.1-KIK

0.64

0.88

3.1_1st staple

0.35

0.88

3.1_2nd staple

0.58

0.84

3.1+Gly

0.39

0.81

3.1+Amb

0.42

0.80

3.1+GG

0.43

0.82

3.1+AA

0.70

0.90

3.1-KIK+AA

0.67

0.90
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Figure 3.6. Modifications to lead compound, Peptide 3.1, affect helicity of peptides
in water (A) by circular dichroism spectroscopy. Despite the modification, peptides
all exhibit similar helical character in 40% TFE solution (B).
It has been proposed that the regions surrounding the HABDs of RHAMM facilitate the
stabilization of the protein’s secondary structure by their inward positioning that forms a
hydrophobic core [35]. Interestingly, the introduction of a hydrophobic residue (nmethylaminobenzoic acid) into the sequence of this relatively hydrophilic peptide has the
greatest negative effect on binding (Table 3.8, Figure 3.7). It is possible that rather than
forming a hydrophobic core, separating the staples by one hydrophobic residue has a
destabilizing effect on the peptide’s helicity, by increasing the flexibility of the sequence
so that the peptide adopts random coil properties, which would have detrimental effects
on the HA binding properties of the peptide. In a similar manner, a single glycine residue
between the two staples acts to destabilize the peptide, decreasing the peptide’s helicity.
This is immediately juxtaposed by a moderate increase in helicity when the staples are
separated by two glycine residues (0.39 to 0.43 in water). The addition of two residues
allow for the staples to be spaced closer to 3.6 amino acids apart from one another,
facilitating helicity within the peptide backbone. The greatest improvement in helicity
was observed when two alanine residues were added to the sequence (Peptide 3.1+AA).
Alanine has helix-inducing potential and stabilizes helices more than glycine by having a
greater contribution to the hydrophobic effect than glycine as well as having a lower
conformational entropy upon folding [53-55]. In the unfolded state, the backbone polar
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area of alanine is approximately 20.6 Å lower than that of glycine [53]. Alanine is
especially stabilizing when it is positioned in internal helical positions [53]. Therefore,
two alanine residues act to elongate the helices that are formed by the two staples by the
spacing that it confers, and its helix-inducing properties. Interestingly, there is negligible
change in helicity with the loss of the three N-terminal amino acids, but the additional of
the alanine spacer between the staples more than compensates for the loss of amino acids
by improving helical stability and secondary structure.
Table 3.8. Kinetic analysis of 3.1-series peptides
Peptide ID

ka (104/(M*s))

kd (103/s)

KD
(nM)

3.1
3.1-KIK
3.1_1st staple
3.1_2nd staple
3.1+Gly
3.1+Amb
3.1+GG
3.1+AA
3.1-KIK+AA

5.3 ± 0.5

4.7 ± 0.9

23.5 ± 1.3

1.00 ± 0.2

8.0 ± 1.0

2.3 ± 0.1

60.6 ± 3.3
12.2 ± 0.5
17.9 ± 2.4
3.3 ± 0.5

25.9 ± 1.2
9.8 ± 1.0

88.2 ± 2.5

117.4 ± 8.4

7.9 ± 0.5

479.8 ± 15.3

4.9 ± 0.2

381.1 ± 4.5

346.4 ± 10.3

4.0 ± 0.3

553.6 ± 13.1

2.5 ± 0.3

84.7 ± 5.4

4.5 ± 0.5
6.2 ± 0.5

168.4 ± 9.8
89.3 ± 7.2
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Figure 3.7. SPR experiments between modified variants of Peptide 3.1 and 5-10 kDa
HA. Each signal corresponds to the responses of 5 peptide concentrations (750 nM,
1 M, 2.5 M, 5 M, and 10 M). The solid lines indicate a global 1:1 interaction
curve fitting model for each of the interactions.

We observed a relationship between secondary structure stability and the binding
potential of the 3.1-series peptides. This supports past reports in which secondary
structure has been described as being important in order for binding to occur between HA
and RHAMM [34, 35]. As expected, destabilising the linker region of Peptide 3.1 results
in weaker binding to HA than the lead compound, regardless of whether only one of the
two staples was present, or if a spacer was inserted between the two staples. Separating
the two staples with a spacer, such as with a glycine residue or a N-methylamino benzoic
acid residue, resulted in slightly improved affinity for HA than when only one of the two
staples was present. The dissociation rate constants also increased, indicating a decrease
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in specificity of the RHAMM peptide mimetics for HA. This finding suggests that there
may be a need for the increased stability in the linker region that is conferred through the
incorporation of two staples rather than a single one. The exceptions to this, however, are
Peptides 3.1+AA and 3.1-KIK+AA, which have very similar affinities to the lead
compound. This highlights the importance of alpha-helical character in RHAMM, which
is induced by additional Ala residues, on its ability to bind to HA. Interestingly, the loss
of 3 residues from HABD1 (3.1-KIK) results in a negligible decrease in affinity
compared to Peptide 3.1, but this is negated in Peptide 3.1-KIK+AA when two alanine
residues are placed between the two staples, and the binding remains the same. Thus,
Peptide 3.1-KIK+AA yields a compound with superior stability and almost identical
affinity for HA, making it a drug candidate with high potential for treating diseases
ensuing from the RHAMM-HA interaction.

Conclusion
Here, we described the development of the first RHAMM-based drug prototype for
interfering with HA-RHAMM interactions. Alpha-helicity is an inherent property of the
RHAMM protein, which facilitates binding to its ligand, hyaluronan, and its endogenous
activity. The RHAMM peptide mimetics described here were cyclized by two (i, i+4)
lactam bridge staples placed in the linker region between the two HABDs in order to
improve helicity, HA binding, and bioactivity both in culture and in vivo over the linear
compound. One lead compound, Peptide 3.1, was identified from a structure activity
relationship analysis, and was validated for the ability to block inflammation in culture
and in vivo. From this compound, the sequence was successfully optimized in order to
create a metabolically stable peptide with strong affinity for its target that can be further
investigated as a prototypical drug molecule.

Methods
3.4.1

General Methods

All Fmoc-protected amino acids were obtained from ChemImpex. HCTU, HATU, and
Rink Amide MBHA resin (4-(2’,4’-dimethoxyphenyl-(9-fluorenylmethoxycarbonyl)aminomethyl)-phenoxy-acetamidonorleucyl-4-methyl benzhydrylamine resin) were
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obtained from ChemImpex. Tetrakis(triphenylphosphine)palladium (0), phenylsilane, and
Fmoc-AEEA-OH spacer were obtained from Sigma-Aldrich. All solvents were obtained
from Fisher Thermo-Scientific.

3.4.2

Synthesis of peptides

All peptides were synthesized by applying fluorenyl-9-methoxycarbonyl (Fmoc) solid
phase peptide synthesis. Synthesis was conducted on a 0.1 mmol scale using Rink amide
MBHA (0.39 mmol/g), with a four-fold excess of Fmoc protected L-amino acids. Amino
acids were coupled with HCTU (4 eq.) in DMF and DIPEA (6 eq.). All coupling
reactions were carried out at room temperature for 45 minutes with vortexing. The Fmoc
group was removed using 2 treatments of 20% piperidine/DMF for 15-minute and 5minute periods. Following synthesis, the resin was washed with dichloromethane.
Cleavage of the peptide was carried out by treating the resin with TFA: water:
triisopropylsilane (95:2.5:2.5 v/v) for 5 hours. The cleaved peptide was then precipitated
with cold TBME, and was then pelleted by centrifugation at 3000 rpm for 10 min. After
decanting the supernatant, the peptide pellet was rinsed with TBME, resuspended by
vortexing, and centrifuged again. The ensuing peptide pellet was dissolved in water,
frozen and lyophilized until a dry, solid powder was obtained.
Purification was carried out using a reversed-phase preparative HPLC column (Agilent
Zorbax SB-C18 column 21.2 x 150 mm, 5 m) and analyzed on a reversed-phased
analytical HPLC column (Agilent Zorbax SB-C18 column 4.6 x 150 mm, 3.5 m). This
system was outfitted with a Waters 600 136 controller, Waters Prep degasser, and Waters
MassLynx software (version4.1). The mobile phases employed were 0.1% TFA in water
(solvent A) and 0.1% TFA in acetonitrile (solvent B). The flow rate for the preparative
HPLC was set at 20 mL/min and with a flow rate of 1.5 mL/min over 15 minutes for the
analytical system. The absorbance was monitored using a Waters 2998 Photodiode array
detector set at 220 nm, 254 nm, and 400 nm. The collected fractions were then
lyophilized to a solid, and subsequently analyzed by analytical RP-HPLC (220 nm).
All peptides were purified by the above-mentioned protocol at a gradient of 20% to 35%
with a retention time of 9-10 minutes.
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3.4.3

Lactam bridge formation

Double-staple containing peptides were synthesized by Fmoc-based SPPS. Each staple
was synthesized separately; the peptide was synthesized from its C-terminus to the Nterminus of the first lactam bridge, followed by selective deprotection of the orthogonal
protecting groups (allyloxycarbonyl and allylester) on the side chains of the residues
creating the staple. The two side chains were coupled with the N-terminal Fmoc group
still in place. The remainder of the peptide was then synthesized and the second staple
was formed as before.
Allyloxycarbonyl and the allylester protecting groups on the lysine and glutamic acid
groups, respectively, were deprotected with phenylsilane (24 eq) in DCM to the resinbound peptide, flushing with nitrogen, and shaking for 5 minutes.
Tetrakis(triphenylphosphine) palladium (0) (0.1 eq) was then added to the mixture and
the peptide vessel was again flushed with nitrogen. This reaction was allowed to proceed
for 10 minutes. The resin was subsequently washed with DCM (4 x 30 s), followed by a
series of washings with DCM, DMF, MeOH, DMF, DCM (30 s each). Cyclization was
carried out with HATU (3 eq) and DIPEA (6 eq) in DMF for a minimum of 2 hours.
Following successful cyclization, the N-terminal Fmoc group was deprotected with 20%
piperidine/DMF for 15 minutes. The peptide was acetylated with 2 treatments of 20%
acetic anhydride/DMF for 30 minutes each.

3.4.4

Circular Dichroism spectroscopy

CD was carried out on a Jasco J-810 spectropolarimeter and recorded in the range of 180260 nm. The peptides were dissolved in Milli-Q water, and in a 40% TFE/water solution
at a concentration of 0.25 mg/mL. The measurements were carried out at 20ᴼC, using a
quartz cuvette with a path length of 1mm. The instrument measured at a scanning speed
of 10-50 nm/min, and averaged five individual data points in order to obtain the reported
CD spectrum. A blank solution of Milli-Q water, and 40% TFE/water were run before the
measurements, and the spectra were baseline corrected.
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3.4.5

Synthesis of HA-Cystamine

5-10 kDa HA (purchased as sodium hyaluronate, Lifecore Biomedical) was dissolved in
DMSO/H2O (7/3, v/v), and was reacted with excess sodium cyanoborohydride for 12
hours at room temperature. 10 equivalents of cysteamine hydrochloride (Sigma Aldrich)
was added, and the reaction proceeded for an additional 24 hours. The solution was then
dialyzed exhaustively in deionized water for 3 days using a 3.5-5 kDa dialysis tube
(Float-a-Lyzer, Spectrum Labs) with a biotech grade cellulose ester membrane.

3.4.6

HA binding

All experiments were carried out on an OpenSPRTM instrument (Nicoya Lifesciences) at
25 C, equipped with a 100 L loading loop. Gold nanoparticle (100 nm) biosensors were
purchased from Nicoya Lifesciences. All experiments were carried out in phosphate
buffered saline (PBS) running buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2
mM KH2PO4), pH 7.4. The gold biosensors were incubated with cystaminefunctionalized 5-10 kDa HA (3mg/mL) for 3 days. Available binding sites on the chip
surface were blocked with poly (ethylene glycol) methyl ether thiol (2 mg/mL) (Sigma
Aldrich). The peptide ligands were dissolved in PBS at varying concentrations, and were
injected at a flow rate of 50 L/min when the baseline was stabilized. Regeneration of the
chip surface was carried out with 1 M NaCl, and no further injections were done until the
baseline was stable. The data was processed and analyzed using Tracedrawer software
(Ridgeview Instruments AB). Kinetic parameters were calculated using a global analysis,
fitting the data to a 1:1 model.

3.4.7

Serum stability

Each peptide (1 mM final concentration) was incubated in a mixture of 25% human
serum (Sigma-Aldrich, Male type AB cat# H4522) in PBS (pH 7.4, 450 L final volume,
DMSO final concentration 0.5%) at 37 °C. At appropriate time intervals, aliquots of
peptide solution were removed and mixed with either acidic solutions (4% phosphoric
acid, pH 1-2) or basic (4% ammonium hydroxide, pH 11-13) to dissociate peptide
interactions with components of human serum. Peptide was isolated from human serum
by column separation on Oasis® sorbent 96-well μElution plates (HLB- amphiphilic
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resin and MCX-cation exchange resin) and manifold. The extracted peptide was
quantified on an Acquity UHPLC-MS system (Waters Co.). Peptide was quantified by
measuring the peak area of a peptide specific M+n ion peak (average of 3 replicates).
Percent abundance of peptide peak area relative to peptide peak abundance at T0 was
plotted as a function of time. Peptide half-life was calculated by optimized curve fitting
(linear, 2-parameter or 3-parameter exponential decay curve) on SigmaPlot™ and solving
for time at 50% peptide peak abundance.

3.4.8

Inflammation protein array

Commercially available murine RAW 264.7 macrophages carrying a SEAP reporter gene
(RAW-Blue; InvivoGen, San Diego, CA, USA) were used. Cells were grown to 80%
confluence in DMEM containing 4.5 g/L glucose, 10% heat-inactivated fetal bovine
serum, 2 mM L-glutamine, 50 μg/mL penicillin/streptomycin, 100 μg/mL Normocin
(InvivoGen) at 37 °C in 5% CO2.
For peptide screening experiments, cells were scraped in growth medium, counted, and
plated to flat-bottom 96-well plates at a density of 5x104cells/well either in the presence
or absence (control) of 200 ng/mL TLR1/TLR2 agonist PAM3CSK4 (InvivoGen).
RHAMM peptides were added in 6 replicate wells at a dose of 10ng/mL in the presence
of PAM3CSK4. After 18 hours of stimulation, reverse phase protein microarray
membrane was incubated in the supernatants collected from the RAW-Blue cells. After
20 minutes of incubation at 37 °C, a general secondary antibody was washed over the
membrane, and the SEAP levels were determined using spectrophotometry at a
wavelength of 630 nm.

3.4.9

RANTES ELISA

RANTES levels were also measured in the supernatants of stimulated RAW-Blue cells by
sandwich ELISA (mouse Quantikine TNFα ELISA; R&D Systems, Minneapolis, MN,
USA) following manufacturers protocol.
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3.4.10

Lipopolysaccharide mouse assay

Peptide 3.1 was converted from its TFA salt form to the acetate salt with three
incubations in a 25% acetic acid solution. It was dissolved in PBS buffer and was
sterilized by filtration through a 0.22 m filter. 5-week old C57BL/6 female mice
(Charles River) were housed for one week prior, and were subsequently injected
subcutaneously with Peptide 3.1 (9 mg/kg, 1.85 M). A second dose of the same
concentration of peptide was injected 18-20 hours after the first injection. Mice in the
control group and LPS only group received an injection of PBS buffer instead of peptide.
All mice were injected with buprenorphine (subcutaneous, 0.2mg/kg). Mice in the
peptide treated and LPS only control groups were injected with LPS (intraperitoneal (IP),
5 mg/kg) 1 hour after the second peptide injection. The control group did not receive
LPS. The mice were anesthetized by isoflurane inhalation 30 minutes after the LPS
injection, and blood was drawn by cardiac puncture. The serum was isolated by
centrifugation at 4 °C for 10 min at 13 000 RPM. An ELISA was carried out to quantify
serum concentration of TNF- .
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Figure S 3.1. HPLC trace of Linear peptide (Ac-KIKHVVKLKDENSQLKSEVSKL
RSQLVKRK-NH2)
AHK-02-145-qc10-20to50-Agilent-15min
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Figure S 3.2. HPLC trace of Peptide 3.1 (Ac-KIKHVVKLK [EENSK]-[EKSEK]
SKLRSQLVKRK-NH2)
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Figure S 3.3. HPLC trace of Peptide 3.2 (Ac-KIKHVVKLKD [ENSQK]-[ESEVK]
KLRSQLVKRK-NH2)
AHK-02-149-qc10-20to50-Agilent-15min
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Figure S 3.4. HPLC trace of Peptide 3.3 (Ac-KIKHVVKLK [EENSK]-[KKSEE]
SKLRSQLVKRK-NH2)
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Figure S 3.5. HPLC trace of Peptide 3.4 (Ac-KIKHVVKLK[KENSE]-[EKSEK]
SKLRSQLVKRK-NH2)
AHK-03-13-qc11-20to60-Agilent-15min
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Figure S 3.6. HPLC trace of Peptide 3.1-KIK (Ac-HVVKLK [EENSK]-[EKSEK]
SKLRSQLVKRK-NH2)
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Figure S 3.7. HPLC trace of Peptide 3.1_1st staple (Ac-KIKHVVKLK [EENSK]LKSEV SKLRSQLVKRK-NH2)
AHK-03-19-qc44-20to80-Agilent-15min
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Figure S 3.8. HPLC trace of Peptide 3.1_2nd staple (Ac-KIKHVVKLK DENSQ[EKSEK] SKLRSQLVKRK-NH2)
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Figure S 3.9. HPLC trace of Peptide 3.1+Gly (Ac-KIKHVVKLK [EENSK]-Gly[EKSEK] SKLRSQLVKRK-NH2)
Default file
AHK-05-95-qc27-266-AA-20to60-Agilent

2: Diode Array
Range: 2.001

9.20

1.6

1.4

1.2

AU

1.0

8.0e-1

6.0e-1

4.0e-1
1.42

2.0e-1
1.16

0.0
0.00

1.00

2.00

3.00

4.00

5.00

6.00

7.00

8.00

9.00

10.00

11.00

12.00

13.00

14.00

Time
15.00

Figure S 3.10. HPLC trace of Peptide 3.1+Amb (Ac-KIKHVVKLK [EENSK]-Amb[EKSEK] SKLRSQLVKRK-NH2)
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2: Diode Array
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Figure S 3.11. HPLC trace of Peptide3.1+GG (Ac-KIKHVVKLK [EENSK]-G-G[EKSEK] SKLRSQLVKRK-NH2)
AHK-03-45-qc10-20to60-Agilent-15min
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Figure S 3.12. HPLC trace of Peptide 3.1+AA (Ac-KIKHVVKLK [EENSK]-A-A[EKSEK] SKLRSQLVKRK-NH2)
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Figure S 3.13. HPLC trace of Peptide 3.1-KIK+AA (Ac-HVVKLK [EENSK]-A-A[EKSEK] SKLRSQLVKRK-NH2)
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15.00
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Table S 3.1. Expected and observed double stapled RHAMM peptide mimetics and
the linear counterpart
Peptide ID

Expected m/z

Observed m/z

Linear

[M+4H]4+ = 897.55

[M+4H]4+ = 897.43

[M+5H]5+ = 718.24

[M+5H]5+ = 718.14

[M+6H]6+ = 598.70

[M+6H]6+ = 598.61

[M+7H]7+ 513.46

[M+7H]7+ =513.24

[M+5H]5+ = 722.84

[M+5H]5+ = 722.78

[M+6H]6+ = 602.54

[M+6H]6+ = 602.48

[M+7H]7+ =516.75

[M+7H]7+ =516.55

[M+8H]8+ = 452.15

[M+8H]8+ = 452.11

[M+5H]5+ = 722.44

[M+5H]5+ = 720.03

[M+6H]6+ = 602.20

[M+6H]6+ = 600.20

[M+7H]7+ =516.46

[M+7H]7+ =516.26

[M+8H]8+ = 451.90

[M+8H]8+ = 451.86

[M+5H]5+ = 722.84

[M+5H]5+ = 722.37

[M+6H]6+ = 602.54

[M+6H]6+ = 602.14

[M+7H]7+ =516.75

[M+7H]7+ =516.54

[M+8H]8+ = 452.15

[M+8H]8+ = 452.11

[M+5H]5+ = 722.84

[M+5H]5+ = 722.22

[M+6H]6+ = 602.54

[M+6H]6+ = 602.40

[M+7H]7+ =516.75

[M+7H]7+ =516.53

[M+8H]8+ = 452.15

[M+8H]8+ = 452.09

Peptide 3.1

Peptide 3.2

Peptide 3.3

Peptide 3.4
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Figure S 3.14. ESI+ Mass Spectrum for Linear peptide (Ac-KIKHVVKLKDENSQL
KSEVSKLRSQLVKRK-NH2)
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Figure S 3.15. ESI+ Mass Spectrum for Peptide 3.1 (Ac-KIKHVVKLK [EENSK][EKSEK] SKLRSQLVKRK-NH2)
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MK-0267-T1-1-stability-2-16-2017 1226 (1.715) Cm (1202:1228)

1: TOF MS ES+
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Figure S 3.16. ESI+ Mass Spectrum for Peptide 3.2 (Ac-KIKHVVKLKD [ENSQK][ESEVK] KLRSQLVKRK-NH2)
MK-0268-T1-1-stability-2-16-2017 896 (1.267) Cm (884:922)
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Figure S 3.17. ESI+ Mass Spectrum for Peptide 3.3 (Ac-KIKHVVKLK [EENSK][KKSEE] SKLRSQLVKRK-NH2)

m/z
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MK-0268-T1-2-stability-2-16-2017 886 (1.256) Cm (885:903)
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Figure S 3.18. ESI+ Mass Spectrum for Peptide 3.4 (Ac-KIKHVVKLK[KENSE][EKSEK] SKLRSQLVKRK-NH2)
Table S 3.2. Calculated and observed m/z values for Peptide 3.1-series peptides
Peptide ID

Expected m/z

Observed m/z

Peptide 3.1-KIK

[M+4H]4+ = 810.98

[M+4H]4+ = 811.25

[M+5H]5+ = 648.99

[M+5H]5+ = 649.02

[M+6H]6+ = 540.99

[M+6H]6+ = 541.01

[M+7H]7+ =464.00

[M+7H]7+ =464.01

[M+4H]4+ = 892.06

[M+4H]4+ = 892.06

[M+5H]5+ = 713.85

[M+5H]5+ = 713.85

[M+6H]6+ = 595.04

[M+6H]6+ = 595.04

[M+7H]7+ =510.32

[M+7H]7+ =510.32

[M+8H]8+ = 446.53

[M+8H]8+ = 446.53

Peptide 3.1_1st staple

m/z
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Peptide 3.1_2nd staple

Peptide 3.1+Gly

Peptide 3.1+Amb

Peptide 3.1+GG

Peptide 3.1+AA

Peptide 3.1-KIK+AA

[M+4H]4+ = 899.79

[M+4H]4+ = 899.79

[M+5H]5+ = 720.03

[M+5H]5+ = 720.03

[M+6H]6+ = 600.20

[M+6H]6+ = 600.20

[M+7H]7+ =514.74

[M+7H]7+ =514.74

[M+8H]8+ = 450.40

[M+8H]8+ = 450.40

[M+4H]4+ = 917.56

[M+4H]4+ = 917.56

[M+5H]5+ = 734.25

[M+5H]5+ = 734.26

[M+6H]6+ = 612.04

[M+6H]6+ = 612.07

[M+7H]7+ =524.89

[M+7H]7+ =524.78

[M+8H]8+ = 459.28

[M+8H]8+ = 459.67

[M+5H]5+ = 749.48

[M+5H]5+ = 749.69

[M+6H]6+ = 624.73

[M+6H]6+ = 625.23

[M+7H]7+ =535.77

[M+7H]7+ =535.63

[M+8H]8+ = 468.80

[M+8H]8+ = 469.07

[M+5H]5+ = 745.65

[M+5H]5+ = 745.69

[M+6H]6+ = 621.54

[M+6H]6+ = 621.58

[M+7H]7+ = 533.04

[M+7H]7+ = 533.07

[M+8H]8+ = 466.41

[M+8H]8+ = 466.42

[M+5H]5+ = 751.26

[M+5H]5+ = 751.69

[M+6H]6+ = 626.22

[M+6H]6+ = 626.25

[M+7H]7+ = 537.04

[M+7H]7+ = 536.92

[M+8H]8+ = 469.91

[M+8H]8+ = 469.92

[M+4H]4+ = 846.50

[M+4H]4+ = 846.40

[M+5H]5+ = 677.40

[M+5H]5+ = 677.43

[M+6H]6+ = 564.67

[M+6H]6+ = 564.85

[M+7H]7+ = 484.29

[M+7H]7+ = 484.29

117

AHK-06-29-266-KIK-qc26-05to40 970 (1.249) Cm (951:973)
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Figure S 3.19. ESI+ Mass Spectrum for Peptide 3.1-KIK (Ac-HVVKLK [EENSK][EKSEK] SKLRSQLVKRK-NH2)
AHK-04-99-266-1st-qc16-17-05to40 1118 (1.438) Cm (1112:1143)
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Figure S 3.20. ESI+ Mass Spectrum for Peptide 3.1_1st staple (Ac-KIKHVVKLK
[EENSK]-LKSEV SKLRSQLVKRK-NH2)
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AHK-04-101-266-2nd-qc20-21-05to40 847 (1.095) Cm (836:850)

1: TOF MS ES+
530

603.3844

100
517.3247

603.5557

517.4689
517.6130

517.1805 517.7428

603.2133

%

517.8870

603.7114

518.0313

603.8827

452.9156
453.2933
452.6594

604.1631
518.1754
604.3344

453.4282

518.3197

499.0392

0

400

450

723.8721
723.6675
724.4519

604.5057
582.0323

500

550

600

650

700

750

800

850

900

950

1000

m/z

Figure S 3.21. ESI+ Mass Spectrum for Peptide 3.1_2nd staple (Ac-KIKHVVKLK
DENSQ-[EKSEK] SKLRSQLVKRK-NH2)
AHK-04-141-2-266-Gly-qc20-22-05to40 834 (1.079) Cm (824:845)
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Figure S 3.22. ESI+ Mass Spectrum for Peptide 3.1+Gly (Ac-KIKHVVKLK
[EENSK]-Gly-[EKSEK] SKLRSQLVKRK-NH2)
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Figure S 3.23. ESI+ Mass Spectrum for Peptide 3.1+Amb (Ac-KIKHVVKLK
[EENSK]-Amb-[EKSEK] SKLRSQLVKRK-NH2)
AHK-06-31-266-GG-qc22-05to40 904 (1.166) Cm (894:919)
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Figure S 3.24. ESI+ Mass Spectrum for Peptide3.1+GG (Ac-KIKHVVKLK
[EENSK]-G-G-[EKSEK] SKLRSQLVKRK-NH2)
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AHK-06-57-266-AA-qc27-05to40 995 (1.280) Cm (981:995)
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Figure S 3.25. ESI+ Mass Spectrum for Peptide 3.1+AA (Ac-KIKHVVKLK
[EENSK]-A-A-[EKSEK] SKLRSQLVKRK-NH2)
AHK-06-87-266-KIK-AA-qc18-05to40 994 (1.279) Cm (988:995)
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Figure S 3.26. ESI+ Mass Spectrum for Peptide 3.1-KIK+AA (Ac-HVVKLK
[EENSK]-A-A-[EKSEK] SKLRSQLVKRK-NH2)
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Figure S 3.27. CD spectra of double stapled Peptides 1-4 (B-E) and their linear
counterpart (A) showing helicity in water and 40% TFE solution. Peptides were run
at 0.25 mg/mL
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Figure S 3.28. CD spectra of modified double stapled peptides, in which the linker
region and N-terminal sequence of Peptide 3.1 were modified. All peptides were run
at 0.25 mg/mL in water and 40% TFE solution
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Figure S 3.29. Serum stability of Peptides 3.1-3.4 and their linear counterpart
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Chapter 4

4

The development of an optical probe for measuring
glomerular filtration rate
Introduction

Glomerular filtration rate (GFR) is a measure of kidney filtering capacity and renal
function, and therefore, is a prognostic indicator of chronic kidney disease (CKD), such
as graded renal artery stenosis. The polysaccharide, inulin, is considered the gold
standard for measuring GFR clinically, as it is freely filtered through the kidneys, without
being reabsorbed or secreted through peritubular capillaries or glomeruli. Therefore, the
amount of inulin that is excreted in urine indicates the volume of plasma that is filtered
by the glomeruli. The classic method of measuring GFR requires continuous intravenous
administration of inulin, precise blood and urine collections over a 3-hour period, and
bladder catheterization in order to ensure complete urine collection [1]. This laborious,
tedious, and invasive method has diminished its clinical value in favour of faster
estimated GFR (eGFR) values that can be easily obtained by endogenous serum
creatinine levels. Unfortunately, the estimation suffers from a number of limitations that
result in underestimated values compared with the physiological value. As a result, there
has been considerable development of exogenous biomarkers for measuring GFR
directly, and include probes that are radioisotopically labeled, such as 125I-iothalamate
[2], 51Cr-ethylenediaminetetraacetic acid (EDTA) [3], and 99mTcdiethylenetriaminepentaacetic acid (DTPA) [4, 5], and those that are non-radioactive,
such as iohexol [6], iothalamate [7, 8], fluorescently labeled sinistrin [9, 10] and
fluorescein-labeled inulin [11, 12].
The measurement of GFR is a multi-faceted process, not only facilitating the detection
and monitoring of chronic kidney disease, but also acts as a pre-screening method for
identifying therapeutic efficiency. Drug dosing and uptake efficiency depends on a
patient’s GFR, as many commonly administered drugs are excreted by the kidneys.
Therefore, accurate measurement of GFR will permit more accurate dosing of drugs, and
result in superior therapeutic outcome with fewer adverse complications.
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Here, we propose the development of an optical probe based on inulin, the current
clinical gold standard renal clearance biomarker, allowing for an efficient method of
measuring GFR by transcutaneous pulse dye densitometer (TPDD) at 788 nm, without
requiring blood sampling or urine collection. No reports exist on the synthesis and
characterization of dye-labeled inulin. Fluorescein-labeled inulin is available
commercially (Sigma Aldrich), but its synthesis is not described and its application is
limited to measurements at 495 nm. It must be noted that the choice of dye used here,
Cy7.5, was directed by the requirement of NIR absorption for enhanced penetration into
human tissue, facilitating the detection of a probe with relative ease, and the convenience
of a NIR dye that is commercially available. The method of synthesis proposed here
allows for the functionalization of inulin with any dye molecule, and thus could satisfy
any absorption wavelength requirement.

Results and Discussion
The novel optical probe described here is based on inulin, which is the current clinical
standard for measuring GFR, and was synthesized by a straightforward method that does
not require the immediate purification of the intermediate. Cy7.5-Inulin was prepared by
a two-step synthesis via a non-toxic intermediate, carboxymethyl inulin (CMI) [13]
(Scheme 4.1). The dye, functionalized with an amine, was conjugated to CMI after
activation with EDC and NHS. The conjugate was then dialyzed exhaustively in water for
a minimum of 3 days to remove any unconjugated dye or unreacted reagents.

Scheme 4.1. 2-step synthesis of Cy7.5-inulin conjugate after CMI intermediate
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Characterization of the starting material, inulin, the intermediate product, CMI, and the
final dye-labeled inulin by FT-IR suggests that modifications made at each step allowed
the successful addition of Cy7.5 to the carbohydrate (Figure 4.1). The appearance of new
absorption signals at 1425 cm-1, correlating with the –C-H bend of the methylene group,
1650 cm-1, corresponding to the N-H bend of an amide, and 1708 cm -1, corresponding to
the carbonyl group of an amide, confirm the addition of the amine-functionalized dye to
the inulin polysaccharide chain. The spectrum for inulin indicates that there might be a
carbonyl in inulin (1660 cm-1), which indicates that the polysaccharide’s reducing end
may be in its open chain form.

Figure 4.1. FT-IR spectrum showing shift in peaks as inulin is modified to CMI and
Cy7.5-inulin conjugate and new functional groups are added
This transformation was further monitored by 1H (Figure S4.1) and 13C NMR
spectroscopy (Figure S4.2). The conversion of inulin to CMI is noted by the appearance
of the carboxylic signal (COOH) at two sites (162.97 ppm and 176.66 ppm), which were
then converted to the amide (CONH) following the addition of the dye, with new
carbonyl amide signals shifting to 158.76 ppm and 173.27 ppm, respectively (Figure
S4.2). Signals representing Cy7.5 were observed in the aromatic region for the final
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product, which matched those of the commercial dye. We observed unreacted
chloroacetic acid (169.97 ppm) in the carbon NMR of CMI, but noted that it was no
longer present in the final dye-labeled conjugate, as the final conjugate is exhaustively
purified by dialysis over 3-4 days, removing any unreacted reagents, including unreacted
dye. We determined from the ratio of aromatic proton signals (associated with the dye) to
signals identified as being part of the carbohydrate polymer (4.5 ppm to 5.5 ppm), that
there are approximately 1-2 dye molecules per 10 sugar units, or approximately 2-4 dye
molecules per inulin molecule (Figure S4.1). This was confirmed by absorption, in
which a known amount of dye-conjugated inulin was measured by UV-Vis and compared
with a standard curve of dye alone in order to determine the amount of dye by weight for
each sample. Dye-loading efficiency ranged from 5% to 25%.
Mass analysis was carried out using matrix-assisted laser desorption/ionization mass
spectrometry (MALDI-MS) (Figure 4.2) and electrospray ionization mass spectrometry
(ESI-MS) (Figure 4.3), both of which confirmed the starting material as inulin by the 162
Da mass difference between peaks, correlating with glucose and fructose residues.
However, because of the number of potential charged states produced from a single
compound in ESI, poor ionization potential of polysaccharides, and the number of
different sized sugar molecules present, we monitored the transformation from inulin to
dye conjugate using MALDI, which produces singly charged ions almost exclusively
[14]. In the spectrum, we were able to identify sodiated adducts, which agrees with the
previously reported data for inulin [15, 16], and for each signal, we observed a
corresponding signal of the polysaccharide with the reducing end residue (additional
18.015 Da). Reflectron mode and linear mode were used for the polysaccharides, and we
observed fragmentation of the polysaccharides in both modes, with fructans containing
from 3 to 25 residues being identified. This was unexpected, although fragmentation of
large polymers to smaller ions during the MALDI process despite its soft ionization has
been reported before for polysaccharides [17, 18]. ESI-MS disproved the size variability
observed in MALDI, instead indicating the presence of a mixture of fructans containing
11 to 25 residues, with peaks assigned to the mass of the doubly charged molecular ion,
which was calculated as twice the mass of 81.07n (mass of fructan units) + 38.96 (K
mass) + 18.015 (additional mass of the reducing end residue), where n is the number of
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fructose units [17, 19]. The identification of sodium and potassium adducts by both mass
spectrometry techniques confirms the presence of contaminants from the glass and plastic
vials or plates, which can easily ionize with significant signal to noise ratios [20].

Figure 4.2. MALDI-MS of Inulin (A) and carboxymethyl inulin (CMI) (B) using
DHB as matrix, acquired in reflectron mode. Masses were observed as sodiated
adducts. A mass difference of 162 was observed for both inulin and CMI, and a
mass difference of 57 Da was observed between inulin and CMI (boxed) (B).

Figure 4.3. ESI-MS spectrum of inulin
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A mass difference of 57 Da was observed between inulin and CMI, correlating with the
mass of acetic acid to inulin (Figure 4.2B). However, there is an incomplete conversion
of inulin to CMI, and starting material persists following the modification. It is unclear if
each polysaccharide is equally modified with the same number of modified fructans per
molecule, or if the number of modified monomers varies. Complete conversion is
difficult to achieve [21], and the efficiencies of modifications of different sizes of
polysaccharides vary. The range in number of carboxymethylated sites in CMI directly
results in a range in the number of dye-conjugated sites in Cy7.5-inulin, where the
maximal number of sites that can accept a dye molecule depends directly on the number
of modified sites in CMI. Inconsistencies in the number of modified sites in CMI are not
expected to cause any negative toxic effects, as both inulin and CMI have been
conclusively determined to be non-toxic in humans, and the mixture of inulin and CMI is
expected to be freely filtered by the kidneys without inducing tubular secretion or
reabsorption [13]. Similarly, disparities in the number of dye-conjugated sites is not
expected to affect toxicity as the conjugate’s hydrodynamic diameter falls significantly
below the average minimum capillary size of 4 microns [22] (Figure 4.4).
MALDI produced inconclusive results for the conjugate, instead resulting in the loss of
the dye molecule from the polysaccharide, as well as a repeating signal pattern of 71 Da
(Figure S4.3), which does not correlate with the mass of the sugar molecules or portions
of the dye that could be reasonably fragmented. It is unlikely that the dye is fragmenting
into smaller ions, or that the fructan units are breaking apart. We believe that MALDI is
an insufficient method of monitoring the addition of the dye to the polysaccharide.
Despite the wide use of MALDI for polysaccharide analysis, the technique may not be an
ideal method for characterizing the modification of sugars, due to its relatively poor mass
accuracy and polydispersity of polysaccharides, and may explain why it has not been
successfully used for analyzing large linear polysaccharides to date [18]. In fact, MALDI
is approximately 1500 times more efficient for proteins than for polysaccharides of the
same mass [18]. However, analysis by dynamic light scattering (DLS) confirmed there
was an increase in hydrodynamic diameter during the modification of inulin and the
formation of the conjugate (Figure 4.4). Interestingly, two average size populations of
starting material, inulin, are present, which when modified to the intermediate, are more
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homogenous in size. An increase in average size from ~10 nm for inulin to ~25 nm for
CMI, followed by a change to ~90 nm for the dye conjugate was observed. The large size
change from CMI to dye-loaded inulin may be the result of the loading of multiple dye
molecules, which was also determined by NMR, but may also indicate aggregation of the
conjugate.

Figure 4.4. Dynamic light scattering of inulin, CMI, Cy7.5-inulin conjugate
The stability of the conjugate was evaluated by incubation in 25% plasma derived from
volunteer patient blood at 38 °C for different periods over a 2-hour period, at 38 C. After
absorption measurements were taken, the samples were placed on ice to slow down any
plasma-related degradation, and were subsequently centrifuged in centrifugal filter units.
Following centrifugation, water and any particles smaller than the 3 kDa MWCO filter
were pulled down in the eluent, while the conjugate and plasma were retained in the
filter. Little to no change was observed in the absorption measurements following
reconstitution to the same volume as the initial absorption measurements (Figure 4.5),
indicating that both the dye and the dye-carbohydrate site of conjugation are robust
enough for in vivo applications. However, the pharmacokinetic properties of the
conjugate are unknown.
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Figure 4.5. Cy7.5-inulin is stable in plasma from CKD patients over 2 hours. Each
measurement was done in triplicate. The eluent following centrifugation, which
contained water and particles <3 kDa in size, had absorption values < 0.05 at all
time points.
Absorption measurements by UV-Vis spectrophotometry verified the absorption capacity
of the dye-carbohydrate conjugate (Figure 4.6). In plasma alone, obtained from the blood
of volunteer patients with chronic kidney disease (CKD), little is absorbed above 700 nm,
while the conjugate readily absorbs at wavelengths greater than 700 nm. This suggests
that all in vivo measurements taken at wavelengths greater than 700 nm would be
measuring only the dye-carbohydrate conjugate as it circulates through the body and
passes through the glomeruli.
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Figure 4.6. Plasma from patients with chronic kidney disease does not absorb
significantly at 788 nm, where Cy7.5-inulin has its maximal absorption in plasma.
Preliminary evaluation of the conjugate has been carried out in farm-raised pigs with
decreasing GFR from graded renal artery stenosis. Monitoring and analysing the plasma
clearance of the conjugate allows for calculation of both the GFR and the optimal dose of
drugs that filter primarily through the kidneys, such as carboplatin. Drug-related
complications are partly associated with poor plasma clearance, and this subsequently
increases the risk of adverse reactions from the drug. For example, most anticancer drugs
have an optimal area under the curve (AUC) of the plasma drug concentration vs time
curve that leads to the best therapeutic efficacy with a level of acceptable adverse
reaction risks. If the drug is entirely cleared from the body by the kidneys, then the
Calvert formula [23] relates the dosage needed to achieve the optimal AUC with the
patient’s GFR. With the development of an optical marker, such as Cy7.5-inulin, the
procedure for measuring GFR can be greatly simplified. Analogous to the Calvert
formula, GFR determination also depends on the AUC of plasma Cy7.5-inulin clearance
curve, as shown in Figure 4.7.
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Figure 4.7. Transcutaneous pulse dye densitometry reading of Cy7.5-inulin at 805
nm in the plasma of a farm-raised pig after intravenous injection of the dye. GFR
was calculated as the ratio of the amount of dye injected to the AUC, resulting in an
estimated value of 120 mL/min, which is comparable with a GFR of 130 mL/min in
a healthy 70 kg pig [24].

Conclusion
Here, we report the synthesis and characterization of dye-labeled inulin for use as an
optical probe to accurately measure GFR efficiently and non-invasively. This soluble
conjugate will also allow for optimal dosing of drugs that are filtered by the kidneys in
order to achieve the most efficient therapeutic outcome. To our knowledge, there is no
published protocol for the synthesis of dye-labeled inulin, and no commercially available
NIR dye-labeled inulin other than fluorescein-labeled inulin. Following this procedure,
more variations can be produced allowing for a range of applications. The conjugate is
stable under the conditions needed to measure GFR in vivo. Preliminary evaluation of the
probe is currently underway in farm-raised pigs with decreasing GFR from graded renal
artery stenosis.
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Methods
4.4.1

Synthesis of carboxymethyl inulin (CMI)

CMI was synthesized using a method described by Creixell et al. (2010) and SantiagoRodriguez et al. (2013). Inulin (500 mg, DP 22-25) (Alfa Aesar) was dissolved in 2.5 mL
deionized water at room temperature. Cold 10 M NaOH was added slowly in multiple
aliquots, with stirring, for a total volume of 400 L. Chloroacetic acid (276 mg, 2.9
mmol) was added immediately, and the mixture was heated to 70 C for 75 minutes. The
solution was cooled to room temperature, and neutralized with acetic acid. An excess of
cold ethanol was added to precipitate the reaction product. The product was then pelleted
by centrifugation and lyophilized until a dry, solid powder was obtained.

4.4.2

Cy7.5 labeling of CMI

For conjugation of Cy7.5 dye to CMI, the polysaccharide was activated with Nhydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC).
For this to occur, CMI (40-50 mg) was dissolved in water, and 1 molar equivalent of
NHS and EDC were added. Activation was carried out for 1.5 hours with shaking. The
activated CMI solution was subsequently added drop wise to Cy7.5-amine (Lumiprobe)
(10-15 mg, 12.2-18.3 M), dissolved in dimethyl sulfoxide (DMSO). The conjugation of
the dye to CMI was allowed to proceed for 24 hours at room temperature, in the dark
with shaking. The conjugated product was then lyophilized to provide a dry green
crystalline product.

4.4.3

Dialysis of dye-labeled CMI

Cy7.5-conjugated inulin was resolubilized in 10:90 DMSO:water and added to a pretreated biotech cellulose ester membrane dialysis tube (Float-a-Lyzer, Spectrum Labs,
Phoenix, AZ) with a biotech grade cellulose ester membrane. Exhaustive dialysis was
carried out in water with spinning in the dark. Following dialysis, the solution was
lyophilized until a dry green powder was obtained.
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4.4.4

FT-IR (ATR)

All measurements were carried out on a Perkin Elmer Spectrum Two IR Spectrometer,
UATR-unit diamond. IR spectra were analysed using OMNIC 8.2.0.389 (Thermo
Scientific Inc.)

4.4.5

Absorption measurements

All absorption readings were performed on an Agilent Cary 60 UV-Vis
Spectrophotometer, and data was acquired in the Scan and Simple Reads applications
(both version 5.0.0.999) in Cary WinUV version 5.0.0.1005. All optical density (OD)
readings were performed at 406 nm (local maximum) in 50:50 DMSO:water.

4.4.6

Dynamic Light Scattering

All measurements were performed at 25 C using a Zetasizer Nano ZS instrument from
Malvern Instruments. Three measurements, each with a duration of 10 seconds, were
performed at an angle of 173 degrees Backscatter (NIBS default). Three runs, each with a
duration of 10 seconds, were performed. Samples were prepared in Milli Q water at a
concentration of 0.8 mg/mL.

4.4.7

Plasma stability

Blood was obtained from volunteer chronic kidney disease (CKD) patients. Patient
plasma was then obtained by mixing the blood with sodium heparin, and centrifuged to
obtain supernatant.
Cy7.5-inulin conjugate was dissolved in 25% patient plasma. Absorption readings were
taken after t=0 min, 20 min, 40 min, 60 min, 80 min, 100 min, and 120 min of incubation
with plasma. All samples except those in the 0-minute time period were incubated at 38
°C. For those samples that were used for more than one incubation period, after each
absorption measurement was taken at the end of an incubation period, the samples were
placed on ice, and centrifuged at 3000 RPM at 20 °C for 40 minutes in pre-treated
Amicon Ultra-15 Centrifugal Filters, MWCO 3kDa (Merck Millipore Ltd.). The
ultrafiltrate was then incubate with 25% patient plasma for the time required before new
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absorption readings were obtained after the volumes were brought to 1 mL. The
absorption readings from different incubation periods were compared. The National
Research Council Canada’s Research Ethics Board approved the protocols for blood
withdrawals from patients with chronic kidney disease and treatment procedures
described in this study (REB # 108616).

4.4.8

NMR

All spectra were recorded on a Bruker 400 Advance III HD NMR spectrometer (Bruker,
Germany) equipped with an Oxford AS400/54 magnet. The samples were all run in
DMSO-d6 at room temperature, with a delay D1 of 10 seconds in the carbon to ensure
full relaxation of the carbonyl signals. The field strength was 100 MHz for carbon, and
400 MHz for proton.

4.4.9

MALDI-TOF-MS

Mass spectrometric data were obtained using an AB Sciex 5800 TOF/TOF System,
MALDI TOF (Framingham, MA, USA). Data acquisition and data processing were
respectively done using a TOF TOF Series Explorer and Data Explorer (both from AB
Sciex). The instrument is equipped with a 349 nm Nd:YLF OptiBeam On-Axis laser. The
laser pulse rate was 400 Hz. Reflectron positive mode was used and each mass spectrum
was collected as a sum of 500 shots. The samples were dissolved in deionized water (1
mg/mL) and mixed with the matrix, 2,5-dihydroxybenzoic acid (DHB), at 1:1 ratio. DHB
was prepared as 20 mg/mL in 50% acetonitrile and 0.1% trifluoroacetic acid.

4.4.10

ESI-MS

Prior to high resolution mass spectrometry (HRMS) analysis, lyophilized inulin was
reconstituted in 5 mM sodium acetate solution to 1 mg/mL, and filtered into a HPLC vial
using a 0.45 um PTFE syringe filter (Chrome Spec). HRMS data was obtained using a QExactive Orbitrap mass spectometer (Thermo Fisher Scientific). The sample was
introduced at 3.0 mL/min by direct injection in positive ESI ionization mode using the
following settings: capillary voltage, 3.9 kV; capillary temperature, 400 °C; sheath gas,
18 units; auxillary gas, 8 units; probe heater temperature, 450 °C; S-Lens RF level, 45.
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Full MS data were obtained using the following conditions: scan range, 500-3000 m/z;
resolution, 70,000; AGC target, 3e6; max IT, 200 ms. Data was processed using Thermo
Xcalibur software.

4.4.11

In vivo Transcutaneous pulse dye densitometry

The Cy7.5-inulin conjugate was dissolved in sterile water and filtered first through a 5
m, followed by a 1.2 m polytetrafluoroethylene (PTFE) filter. The solution was then
injected into the ear vein of a farm-raised pig as a single bolus (1 mg/kg) following
administration of an anesthetic. The signal intensity was monitored by a Nihon Kohden
(NK) TPDD clipped to the tail of the pig, tuned to indocyanine green (ICG), which has a
similar absorption wavelength as Cy7.5. Plasma clearance of the conjugate was
calculated using the the 2-compartmental open model of drug distribution, in which an
administered drug is eliminated from the body by an excretory mechanism. The plasma
clearance curve was fitted by the sum of two decaying exponentials from the time that the
dye equilibrated with the blood pool (t0) to the end of acquisition (tn) of pulse dye
densitometry data. The AUC of the dye plasma curve was then determined by
extrapolation of the fitted biexponential curve to infinity, and the addition of the area
before t0, as the contribution from the vascular phase before dye equilibrium in the blood
pool was achieved. The Animal Use Subcommittee of the Canadian Council on Animal
Care at Western University approved the protocols for all pig handling and treatment
procedures described in this study (protocol 2009092).
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Supplemental Information
Table S 4.1. FTIR analysis of inulin, carboxymethyl inulin, and Cy7.5-labeled inulin

–OH

–NH

–CO

stretch

stretch

stretch

(cm-1)

(cm-1)

(cm-1)

Inulin

3277

–

1130

CMI

3217

–

3320

3320

Polymer

C7.5-inulin
conjugate

–CH

–C=O

–C=C–

–CN

–NH

stretch

stretch

stretch

bend

(cm-1)

(cm-1)

(cm-1)

(cm-1)

–

1660

–

–

–

1134

1425

1600

–

–

–

1123

1442

1708

1604

1228

1650

bend
(alkane)
(cm-1)

Figure S 4.1. Proton NMR spectra of Inulin (A), CMI (B), Conjugate (C). The signal
at 5.15 ppm in inulin corresponds to the anomeric carbon. All samples were run in
DMSO-d6.
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Figure S 4.2. Carbon NMR of Inulin (A), CMI (B), Conjugate (C). All samples were
run in DMSO-d6.

Figure S 4.3. MALDI-MS spectrum of dye-inulin conjugate. Depending on the
sample, the dye was observed to cleave off easily, producing a strong signal (A) and
subsequently fragment (A and B). Mass differences of 71 Da was also observed,
which does not correlate with any mass where the polysaccharide could be easily
fragmented.
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Chapter 5

5

Outlook and conclusions
Outlook and conclusions

This thesis examined two separate principles. The first focused on the RHAMMhyaluronan (HA) interaction and methods for interrupting their association in order to
prevent the progression of diseases related to elevated RHAMM expression. The second
focused on the development and characterization of an optical probe to measure
glomerular filtration rate that is based on the clinical gold standard: the carbohydrate
inulin.
The second chapter studied the development of a target receptor, 7 kDa RHAMM, for
discovering and screening novel RHAMM-binding ligands. 7 kDa RHAMM is a 62amino acid chemically synthesized receptor, and is the first report of a mini-protein with
biological properties that was synthesized by continuous peptide chemistry. 7 kDa
RHAMM was determined to be biologically active in inhibiting the migration of
RHAMM-transfected 10T1/2 (LR21) cells, which we rationalize is the result of the
chemically synthesized receptor blocking the native cell-surface receptor’s motilitystimulating actions. This receptor was revealed to have the important alpha-helical
character that has been described in the native protein [1, 2]. Because reports have
indicated that the protein’s secondary structure is important for it to bind its
polysaccharide ligand, HA [1, 2], we expected the chemically synthesized receptor to
also bind HA because it also exhibits alpha-helical character. This was found to be the
case, and our reported dissociation constant of 8.98 nM is the first quantification of the
RHAMM-HA interaction. The absence of protein-carbohydrate interaction analysis to
date in the literature is most likely due to the lack of readily available full-length
recombinant RHAMM protein. Similarly, new reports on novel RHAMM-binding
ligands have likely been hindered by the lack of available protein for screening. While
the synthesis and purification of recombinant RHAMM has been previously reported [3,
4], it is known to be a challenging process, which is reflected in the commercial price of

144

the recombinant protein. 7 kDa RHAMM was further validated by evaluating its binding
to previously reported tubulin-derived peptides [5]. Using SPR, the tubulin-derived
peptides were determined to have very similar binding affinities to 7 kDa RHAMM as to
recombinant RHAMM. It is therefore concluded that truncating the receptor to 7 kDa in
size and producing it by chemical synthesis are suitable approaches for utilization in drug
development programs for this novel target. This is exciting, as it provides a reliable tool
for screening and discovering new compounds that are currently lacking in the clinic.
The third chapter discusses the development of novel double stapled RHAMM peptide
mimetics for blocking the RHAMM-HA interaction. These double stapled peptides
contain two adjacent lactam bridge staples that lie between both HA binding domains.
The position of the staple within the peptide sequence and the order of amino acids
making up the staples were evaluated and compared with the linear peptide for helicity,
HA-binding potential, stability and bioactivity. A correlation between helicity, binding
affinity and bioactivity was observed, and a lead compound was identified (Peptide 3.1)
(Table 5.1). Peptide 3.1 was further modified to explore the importance of rigidity in the
linker region containing the staple to helicity and HA-binding. This was done by studying
the effect of only one staple vs both staples, and by introducing a spacer between the
staples in the linker region, including a single Gly residue, two residues (Gly and known
helix-stabilizing Ala), and a hydrophobic residue (4-aminomethyl benzoic acid). In
addition, the lead compound was synthesized without the notable cleavage product
following incubation in serum. These efforts resulted in the identification of a new lead
peptide sequence (Peptide 3.1-KIK+AA) that is more stable against enzymatic
degradation than the original compound, with improved helicity and binding to HA.
While the bioactivity of this new compound has yet to be determined, the observed
correlation between helicity, binding affinity, and bioactivity suggests that it will be
active in inhibiting the release of pro-inflammatory cytokines. Similarly, it may have the
potential to inhibit motogenic stimulus from elevated RHAMM expression, and therefore,
have applications in treating cancers that involve RHAMM expression.
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Table 5.1. Lead double stapled RHAMM peptide mimetics and their corresponding
helicities and binding affinities for binding to 5-10 kDa HA
Peptide ID

Sequence

[θ]222

KD

/[θ]208

(nM)

(Water)
3.1

Ac-KIKHVVKLK[EENSK]-[EKSEK]SKLRSQLVKRK-NH2

0.65

88

3.1-KIK+AA

Ac-HVVKLK[EENSK]-AA-[EKSEK]SKLRSQLVKRK-NH2

0.67

89

Elevated RHAMM expression propagates increased levels of fragmented HA, and
therefore, there is an increase in RHAMM-HA interactions at the cell surface [6, 7]. Prior
studies have shown that high RHAMM expression is correlated with highly invasive and
aggressive disease, and in the case of cancer, highly metastatic disease [8]. In the case of
cancer, current treatments are not always effective in targeting the primary tumor, which
can lead to metastasis and poor patient outcome. Thus, there is a clinical need for the
development of novel drug molecules that effectively target cells with aggressive or
metastatic potential. This can be carried out with targeted therapeutics that sequester
fragmented HA before it can activate the signaling cascade, thereby preventing the active
transcription of motogenic and pro-inflammatory genes. While further research into the
pharmacokinetic and pharmacodynamics properties of these compounds is required to
properly validate and translate the peptides to a clinical setting, the double stapled
RHAMM peptide mimetics provide a framework for developing fragmented HA-targeted
therapeutic agents. The identified lead compound, Peptide 3.1-KIK-AA, can be used as
the prototype drug molecule for treating those diseases that are affected by elevated
RHAMM levels or fragmented HA. Specifically, patients suffering from proinflammatory conditions or cancers with RHAMM-overexpressing tumors could receive
Peptide 3.1-KIK-AA as part of the treatment regimen in order to prevent worsening of
the disease or metastatic effects from occurring.
The bioactivity studied in this chapter focused directly on inflammation by measuring the
change in inflammatory cytokine levels before and after treatment with the peptides in
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question. This is an exciting application for therapeutic intervention of the RHAMM
mimetic peptides, and could have potential use in treating inflammation early. However,
other applications of these peptides are certainly viable, several of which have been
explored at a preliminary level and were reported in the patent application No.
PCT/IB2016/051587. Models in which they may have therapeutic application, and in
which they deserve further evaluation, include fibrosis/adipogenesis and wound repair,
specifically invasion and migration. In fact, different RHAMM mimetic peptides that
inhibit the RHAMM-HA interaction were observed to promote adipogenesis and reduce
tissue fibrosis [9], suggesting that the double stapled RHAMM mimetic peptides may
also be effective in this model.
The fourth chapter discussed the development of an optical probe for measuring
glomerular filtration rate (GFR), an indication of kidney function. The current clinical
standard for measuring GFR is by quantifying the rate of renal elimination of inulin,
which is neither metabolized nor reabsorbed by the renal tubules, and therefore passes
through the body intact. The optical probe discussed in this chapter was based on the
inulin structure, but was chemically modified for the conjugation of a dye molecule by
way of a non-toxic intermediate [10]. This was the first detailed report on the synthesis
and analysis of a dye-labeled inulin conjugate. The starting material, the intermediate,
and the final compound were all characterized by a number of analytical techniques in
order to monitor the synthetic progress, as well as determine the efficiency of dyelabeling. In addition, the probe was determined to be stable in serum following 2 hours of
incubation at 38 C, suggesting that dye conjugation results in a stable final product.
Analysis by 1H and 13C NMR spectroscopy and absorption concluded that approximately
2-5 dye molecules per polysaccharide were added, which corresponds to approximately
5% to 25% dye by weight. The range of dye-labeling is not expected to pose toxicity
related complications in vivo, as its diameter falls beneath the average capillary size. In
fact, the probe has been evaluated in vivo in pigs with compromised kidneys, and shows
promise in accurately measuring GFR. In addition to measuring GFR, this probe will
allow for improved dosing of drugs that filter through the kidneys, such as carboplatin, a
commonly administered anticancer drug. Despite its use as an anticancer drug, it results
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in adverse side effects and toxicities, including anemia and the suppression of bone
marrow function [11, 12]. Delivering the optimal dose of drugs like carboplatin would
help ensure that patients receive the optimal therapeutic result with a lower risk of
treatment morbidity or toxicity.
The work carried out in the fourth chapter involved the use of a fluorescent dye. It should
be noted that any dye that absorbs at the right wavelength (788 nm) could be used in
place of a commercially available dye (ℇ = 223 000 L mol-1 cm-1). This could include a
novel synthetic dye, which could potentially be developed at a lower cost than the
commercially available Cyanine dyes, which tend to be quite expensive. A current
challenge faced with the probe is that Cy7.5-amine is not water-soluble, with no
sulfonated versions commercially available. Similarly, the conjugate suffers from
occasional solubility difficulties and is often trapped in the filter. When this occurs, the
filtrate contains strictly conjugate with low dye loading, and is often insufficient for
analysis by transcutaneous pulse dye densitometry (TPDD). Thus, the development of
novel dyes with the appropriate absorption properties that have improved water-solubility
over the current commercially available ones could improve dye-loading and facilitate
the clinical translation of the probe.
In conclusion, this thesis described the development and characterization of chemical
entities that have the potential to facilitate the translation of novel technologies to a
clinical setting. Firstly, the development of 7 kDa RHAMM as a suitable replacement
receptor for screening novel RHAMM-binding compounds will enable the screening and
discovery of new therapeutic and imaging agents, permitting early treatment of diseases
that are correlated with aggressive and metastatic phenotypes. In addition, the
development of double stapled RHAMM peptide mimetics that bind to HA with strong
affinity and that have function blocking activity in inflammation models both in vitro and
in vivo are promising as potential therapeutic agents themselves, or as prototypes for
designing other compounds. Lastly, the development of an optical probe based on the
current clinical gold-standard, inulin, for measuring GFR efficiently and non-invasively,
is exciting, and will allow for improved patient care both in individuals with
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compromised kidneys, as well as other diseases through the minimizing of risk associated
with over- or under-dosing of renal excreted drugs.
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